A Prospective, Multi-center and Noninferiority Clinical Study Evaluating Trochanteric Fixation Nail Advanced (TFNA) in Chinese Patient Population

Statistical Analysis Plan

V1.3

Statistical institution:	Medical Research & Biometrics Center, National Center for Cardiovascular Diseases
Sponsor:	Johnson & Johnson Medical (Shanghai) Ltd.
Date of issue:	May 19, 2020

Confidential Statement

The information contained in this document is proprietary and confidential. Any reproduction, dissemination or distribution, in whatever form and by whatever media, is expressly prohibited without the prior written consent of the contact person of Johnson & Johnson Medical (Shanghai) Ltd.

Signature Page

Study title:	A Prospective, Multi-center and Non-inferiori Trochanteric Fixation Nail Advanced (TFNA) in				
Sponsor:	Johnson & Johnson Medical (Shanghai) Co., Ltd.				
Study No.:	DPS-201502				
Date of issue:	May 19, 2020				
Version No.:	V1.3				
Sponsor/CRO	Title: Signature:	MM/DD/YYYY			
Principal investigator (PI)	Title:	MM/DD/YYYY			
Author of the Plan (NCCD)	Title:	MM/DD/YYYY			
Plan review (NCCD)	Title: Signature:	MM/DD/YYYY			

1/129

Table of Contents

Chapter

Page

		e Page	
		bbreviations and Definitions of Terms	
1.		pduction	
2.		cal Study	
	2.1	Study objective	
	2.2	Study design	
	2.3	Primary endpoint	
	2.4	Secondary endpoints	
3.		stigational Device	
	3.1	Investigational device	
	3.2	Control device	
4.		nded Use and Indications of the Product	
5.		ision and Exclusion Criteria of Subjects	
	5.1	Inclusion criteria	
	5.2	Exclusion criteria.	
6.		eral Statistical Considerations	
	6.1	Study hypothesis	
	6.2	Sample size calculation	
	6.3	Analysis population	
	6.4	Detailed rules for determination of analysis population set and flow chart	
	6.5	Missing values, abnormal values and outlying values	
	6.6	Significant level and statistical analysis software	
-	6.7	Site merging principle	
7.		stical Analysis Indicators and Statistical Analysis Methods	
	7.1	Demographic indicators and other baseline indicators	
	7.2 7.3	Intraoperative information	
		Primary endpoint	
	7.4	Secondary endpoints	
	7.5 7.6	Follow-up data Laboratory examinations	
	7.0	Concomitant medication, adverse events (AEs) or serious adverse events (SAEs)	
8.		eration of Statistical Graphs, Tables and Lists	
	ure 1	Flow chart for determination of analysis population data sets	
Tab		Determination of analysis population	
	ole 2	List of subjects who withdrawal the informed consent or seriously violate the prot	
1 au	27	List of subjects who withdrawal the informed consent of seriously violate the prod	UCUI
Tab	le 3	List of subjects who violate the protocol (CRF collection)	28
Tab	le 4	Determination of analysis population in Beijing Jishuitan Hospital	29
Tab	le 5	Determination of analysis population in Peking University Third Hospital	
Tab	le 6	Determination of analysis population in Chinese PLA General Hospital	
Tab	le 7	Determination of analysis population in the Second Affiliated Hospital of Zheji	iang
Uni	versit	y School of Medicine	32
Tab	le 8	Determination of analysis population in Shanghai General Hospital	33
Tab	le 9	Determination of analysis population in Nanfang Hospital Of Southern Med	lical
Uni	versit	y 34	
Tab	le 10	Determination of analysis population in Affiliated Hospital of Nantong University	35
Tab	le 11	Determination of analysis population in West China Hospital, Sichuan University	36
Tab	le 12	Determination of analysis population in the First Affiliated Hospital of Guangz	hou
Uni	versit	y of Chinese Medicine	
	le 13	Determination of analysis population in the University of Hong Kong - Shenz	vhen
	pital	38	
Tab	le 14	Statistical analysis results of subjects' demographic data	39
м	1. 1.1	Accords & Discretizer Contex National Manier No. VI 0	120

Table 15	Statistical analysis results of subjects' height and body weight40	ስ
Table 16	Statistical analysis results of subjects' previous and current medical history	
Table 16	Statistical analysis results of subjects' previous and current medical history (continued	
1) 43	······································	
Table 16	Statistical analysis results of subjects' previous and current medical history (continued	ł
2) 44		
Table 17	Statistical analysis results of subjects' preoperative SF-12v2 questionnaire45	5
Table 17	Statistical analysis results of subjects' preoperative SF-12v2 questionnaire (continued)
46		
Table 18	Statistical analysis results of subjects' preoperative EQ-5D questionnaire47	
Table 18	Statistical analysis results of subjects' preoperative EQ-5D questionnaire (continued))
48		
Table 19	Statistical analysis results of subjects' preoperative fractures49	
Table 20	Statistical analysis results of subjects' x-ray examination before surgery50	
Table 21	Statistical analysis results of subjects' use of investigational devices	
Table 21	Statistical analysis results of subjects' use of investigational devices (continued)52	
Table 22	Statistical analysis results of subjects' use of other devices	
Table 23	Statistical analysis results of subjects' surgical details	
Table 24	Statistical analysis results of subjects' intraoperative fractures	
Table 24	Statistical analysis results of subjects' intraoperative fractures (continued)50	
Table 25	Statistical analysis results of subjects' evaluation on product operability and tools	
	urgery	
Table 26	Statistical analysis results of subjects' intraoperative AEs	
Table 27	Statistical analysis results of subjects' intraoperative medication records	
Table 28	Statistical analysis results of subjects' intraoperative combination therapy	
Table 29	(FAS) Primary endpoint - statistical analysis results of fracture union rate of subjects a	
	weeks after surgery	
Table 29	(FAS) Primary endpoint - statistical analysis results of fracture union rate of subjects a	t r
	weeks after surgery (continued)	
Table 30	FAS) Primary endpoint - Statistical analysis results of subjects' fracture union rate 24 surgery	
Table 31	o: PPS) Primary endpoint - statistical analysis results of fracture union rate of subjects a) (
	weeks after surgery	
Table 31	(PPS) Primary endpoint - statistical analysis results of fracture union rate of subjects a	
	weeks after surgery (continued)	
Table 32	(PPS) Primary endpoint - Statistical analysis results of subjects' fracture union rate 24	
		•
Table 33	50 surgery	ј 1
	surgery	
Table 34	(FAS) Secondary endpoint - Statistical analysis results of adverse events of subjects68	
Table 35	(FAS) Secondary endpoint - Statistical analysis results of subjects' revision rate 24	
	surgery	
Table 36	(FAS) Secondary endpoint - Statistical analysis results of subjects' re-operation rate 24	
	surgery	
Table 37	(FAS) Secondary endpoint - Statistical analysis results of subjects' Harris hip score 12	
	surgery71	
Table 38	(FAS) Secondary endpoint - Statistical analysis results of subjects' Harris hip score 24	
weeks after s	surgery	
Table 39	(FAS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2	
questionnair	re 12 weeks after surgery73	3
Table 39	(FAS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2	2
questionnair	re 12 weeks after surgery (continued 1)74	4
Table 39	(FAS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2	2
	re 12 weeks after surgery (continued 2)70	5
Table 39	(FAS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2	
questionnair	re 12 weeks after surgery (continued 3)78	8
	arch & Biometrics Center, National Version No.: V1.0 3/129	
Center for Ca	rdiovascular Diseases	

(FAS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 Table 40 questionnaire 24 weeks after surgery......79 (FAS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 Table 40 questionnaire 24 weeks after surgery (continued 1)80 Table 40 (FAS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 (FAS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 Table 40 Table 41 (FAS) Secondary endpoint - Statistical analysis results of subjects' EQ-5D questionnaire (FAS) Secondary endpoint - Statistical analysis results of subjects' EQ-5D questionnaire Table 41 (FAS) Secondary endpoint - Statistical analysis results of subjects' EQ-5D questionnaire Table 42 (FAS) Secondary endpoint - Statistical analysis results of subjects' EO-5D questionnaire Table 42 (FAS) Secondary endpoint - Statistical analysis results of subjects' incidence rate of Table 43 Table 44 (PPS) Secondary endpoint - Statistical analysis results of subjects' AE......90 Table 45 (PPS) Secondary endpoint - Statistical analysis results of subjects' revision rate 24 weeks after surgery 91 Table 46 (PPS) Secondary endpoint - Statistical analysis results of subjects' re-operation rate 24 (PPS) Secondary endpoint - Statistical analysis results of subjects' Harris hip score 12 Table 47 (PPS) Secondary endpoint - Statistical analysis results of subjects' Harris hip score 24 Table 48 (FAS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 Table 49 questionnaire 12 weeks after surgery......95 (PPS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 Table 49 questionnaire 12 weeks after surgery (continued 1)96 Table 49 (PPS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 Table 49 (PPS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 questionnaire 12 weeks after surgery (continued 3)100 Table 50 (PPS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 questionnaire 24 weeks after surgery.....101 (PPS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 Table 50 Table 50 (PPS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 questionnaire 24 weeks after surgery (continued 2)104 (PPS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 Table 50 questionnaire 24 weeks after surgery (continued 3)106 (PPS) Secondary endpoint - Statistical analysis results of subjects' EQ-5D questionnaire Table 51 Table 51 (PPS) Secondary endpoint - Statistical analysis results of subjects' EQ-5D questionnaire 12 weeks after surgery(continue)......108 (PPS) Secondary endpoint - Statistical analysis results of subjects' EQ-5D questionnaire Table 52 Table 52 (PPS) Secondary endpoint - Statistical analysis results of subjects' EQ-5D questionnaire 24 weeks after surgery(continue)......110 (PPS) Secondary endpoint - Statistical analysis results of subjects' incidence rate of Table 53 complications requiring re-operation or revision111 Table 54 Statistical analysis results of subjects' AE evaluation 1 weeks after surgery......112 Table 55 Statistical analysis results of subjects' medication records 1 week after surgery......113 Table 56 Statistical analysis results of subjects' combination therapy 1 week after surgery.....114 Medical Research & Biometrics Center, National Version No.: V1.0 4/129 Center for Cardiovascular Diseases

Table 57	Statistical analysis results of subjects' fractures 1 week after surgery115
Table 58	Statistical analysis results of subjects' x-ray examination at the fracture site 1 week after
surgery	116
Table 59	Statistical analysis results of subjects' AE evaluation 6 weeks after surgery117
Table 60	Statistical analysis results of subjects' medication records 6 weeks after surgery118
Table 61	Statistical analysis results of subjects' combination therapy 6 weeks after surgery119
Table 62	Statistical analysis results of subjects' fractures 6 weeks after surgery120
Table 63	Statistical analysis results of subjects' X-ray examination at the fracture site 6 weeks
after surgery	
Table 64	Statistical analysis results of subjects' AE evaluation 12 weeks after surgery122
Table 65	Statistical analysis results of subjects' medication records 12 weeks after surgery 123
Table 66	Statistical analysis results of subjects' combination therapy 12 weeks after surgery .124
Table 67	Statistical analysis results of subjects' fractures 12 weeks after surgery125
Table 68	Statistical analysis results of subjects' X-ray examination at the fracture site 12 weeks
after surgery	y 126
Table 69	Statistical analysis results of subjects' AE evaluation 24 weeks after surgery127
Table 70	Statistical analysis results of subjects' medication records 24 weeks after surgery 128
Table 71	Statistical analysis results of subjects' combination therapy 24 weeks after surgery .129
Table 72	Statistical analysis results of subjects' fractures 24 weeks after surgery130
Table 73	Statistical analysis results of subjects' x-ray examination at the fracture site 24 weeks
after surgery	y 132
Table 74	Statistical analysis results of outcomes of subjects' complete blood count before and
after surgery	y (before surgery → immediately after surgery)133
Table 74	Statistical analysis results of outcomes of subjects' complete blood count before and
after surgery	y (before surgery → immediately after surgery) (continued)135
Table 75	List of subjects with abnormal complete blood count with clinical significance after
surgery chan	ged from normal indicators before surgery (before surgery \rightarrow immediately after surgery)
136	
Table 76	Statistical analysis results of outcomes of subjects' blood biochemical test before and
	y (before surgery \rightarrow immediately after surgery)137
Table 76	Statistical analysis results of outcomes of subjects' blood biochemical test before and
after surgery	y (before surgery → immediately after surgery) (continued 1)139
Table 76	Statistical analysis results of outcomes of subjects' blood biochemical test before and
	y (before surgery \rightarrow immediately after surgery) (continued 2)141
Table 77	List of subjects with abnormal blood biochemical test indicators with clinical
	after surgery changed from normal indicators before surgery (before surgery \rightarrow
immediately	after surgery)142
Table 78	List of concomitant medication of subjects143
Table 79	Specific description on subjects with AEs144
Table 80	Summary of AEs145
Table 80	Summary of AEs (continued 1)146
Table 81	Specific description on subjects with investigational device-related AEs147
Table 82	Summary of investigational device-related AEs148
Table 82	Summary of investigational device-related AEs (continued)149
Table 83	Summary of AEs (Number of events per subject)150
Table 84	Statistical analysis results of the severity and the device related AEs (According subject)
151	
Table 85	Statistical analysis results of the severity and the device related AEs (Number of events
per subject)	152
Table 86	Specific description on subjects with SAEs154
Table 87	Summary of SAEs155
Table 87	Summary of SAEs (continued)156
Table 88	Specific description on subjects with investigational device-related SAEs157
Table 89	Summary of investigational device-related SAEs158
Table 89	Summary of investigational device-related SAEs (continued)159
Table 90	Summary of SAEs (Number of events per subject)160
	arch & Biometrics Center, National Version No.: V1.0 5/129
Center for Car	diovascular Diseases

Table 91	Statistical analysis results of the severity and the device related SAEs (According subject)
161	
Table 92	Statistical analysis results of the severity and the device related SAEs (Number of events
per subject)	162
Table 93	Specific description on subjects with UADEs164
Table 94	Summary of UADEs165
Table 94	Summary of UADEs (continued)166

Abbreviation	Definition			
GCP	Good Clinical Practice			
CRF	Case Report Form			
SF-12	12-Item Short Form Health Survey			
IRB	Institutional Review Board			
EC	Ethics Committee			
ERB	Ethical Review Board			
BMI	Body Mass Index			
AE	Adverse Event			
SAE	Serious Adverse Event			
UADE	Unanticipated Adverse Device Effect			
ICH-GCP	International Conference on Harmonization - Good Clinical Practice			
HHS	Harris Hip Score			
EQ5D	EuroQol-5D			

List of Abbreviations and Definitions of Terms

1. Introduction

This document provides the specific contents of the statistical analysis plan for a prospective, multi-center and non-inferiority clinical study on the safety and effectiveness of Trochanteric Fixation Nail Advanced (TFNA) manufactured by Johnson & Johnson Medical (Shanghai) Ltd. After all subjects are included and use the implant, the postoperative 24-week (\pm 4 weeks) follow-up is completed or the trial is terminated in advance and the database is forcibly locked, the statistical analysis report for preoperative preparation and postoperative 24-week (\pm 4 weeks) follow-up will be issued for registration application. Refer to the relevant tables, lists and graphs in the statistical analysis plan for the detailed specific analysis.

2. Clinical Study

2.1 Study objective

The primary objective of this study is to evaluate whether fracture union rate, evaluated 24 weeks after proximal femur fracture, for the investigational TFNA intramedullary nail is non-inferior to that for currently available control product PFNA-II in patients with proximal femur fractures.

2.2 Study design

The Trochanteric Fixation Nail Advanced (TFNA) is an implant designed to treat

proximal femur fractures and is currently in use in several regions worldwide (e.g., US, Europe). TFNA is manufactured using a titanium-molybdenum alloy (TiMo) that has not been used for a similar clinical application within China. The study is a prospective, multi-center, controlled, two-arm, randomized, non-inferiority study comparing the 24-week fracture union rate for proximal femur fractures treated with intramedullary nails using investigational devices (TFNA) compared to control devices (Proximal Femoral Nail Antirotation, PFNA-II), under a 10% non-inferiority margin.

2.3 Primary endpoint

The primary endpoint is the fracture union rate 24 weeks after surgery. Fracture union success is a composite endpoint; in order for an individual subject's surgery implanted with TFNA or PFNA-II to be considered successful he/she must satisfy all of the following criteria:

- 1. No focal tenderness or lengthwise percussion pain, or abnormal movement
- 2. The frontal/lateral X-ray examination shows the vague or no fracture gap, or the continuous callus passing across the fracture line
- 3. No deformation or breakage is found in the investigational product

2.4 Secondary endpoints

Secondary endpoints include the safety and effectiveness results, imaging outcomes and adverse events.

- Adverse events (type and frequency) for all adverse events will be compared for the study and control groups
- 24-week revision rate where revision is defined as removal of any component for any reason
- 24-week reoperation rate is defined as secondary surgery at the fracture site(s) for any reason
- Clinical Outcomes
- ► SF-12
- Harris Hip Score
- ► EQ-5D
- Radiographs: incidence of complications such as loosening or cut-out that require reoperation or revision.

3. Investigational Device

3.1 Investigational device

TFNA as the investigational product for this study, including:

- Short nails available in various diameters (Ø9, Ø10, Ø 11, Ø12 mm), lengths (170, 200, or 235 mm) and CCD angle (125°, 130° and 135°). The 235 mm short nail is available for left and right sides.
- Long nails available in various diameters (Ø9, Ø10, Ø 11, Ø12, Ø14mm), lengths (260-480mm in 20mm increments) and CCD angle (125°, 130° and 135°). All long nails are available for left and right sides.
- Head elements are available in blade and screw (both are 70-130 mm in length, available in 5mm increments)
- Locking screws (4.2mm diameter and available in lengths from 26-80mm (2mm increments) or 80-100mm (5mm increments)
- End caps available in 0, 5, 10 and 15mm lengths

3.2 Control device

PFNA-II as control product for this study, including:

- Short nails available in various diameters (Ø9, Ø10, Ø 11, Ø12 mm), lengths (170, 200, or 240 mm) and CCD angle (125° and 130°). The 240 mm short nail is available for left and right sides.
- Long nails available in various diameters (Ø9 and Ø10mm), lengths (260-340mm in 20mm increments and 340-420mm in 40mm increments) and CCD angle (125° and 130°). All long nails are available for left and right sides.
- Head elements are available in blade (70-120 mm in length, available in 5mm increments)
- Locking screws (4mm diameter and available in lengths from 16-60mm (2mm increments), 60-80mm (4mm increments) or 80-100mm (5mm increments)
- End caps available in 0, 5, 10 and 15mm lengths

4. Intended Use and Indications of the Product

The intended use for TFNA is the following:

Intended Use: intended for the treatment of proximal femur and combinations of proximal and shaft fractures of the femur

The indications of the TFNA are:

- Short Nails (lengths 170 mm, 200 mm, 235 mm)
- Pertrochanteric fractures (31-A1 and 31-A2)
- Intertrochanteric fractures (31-A3)
- 235 mm nails are additionally indicated for high subtrochanteric fractures

10/129

- Long Nails (lengths 260 mm 480 mm)
- Pertrochanteric fractures (31-A1 and 31-A2)
- Intertrochanteric fractures (31-A3)
- Fractures of the trochanteric area (31-A1/A2/A3) with diaphyseal extension
- Combined fractures of the trochanteric area (31-A1/A2/A3) and the femoral shaft (32-A/B/C)
- Pathological fractures, including prophylactic use
- Malunion
- Nonunion

5. Inclusion and Exclusion Criteria of Subjects

5.1 Inclusion criteria

Subjects who meet all of the following inclusion criteria will be eligible for participation in the study:

- 1) Age ≥ 18 years
- 2) Patients with unilateral proximal femur fractures that will be treated with intramedullary nail internal fixation
- 3) According to AO fracture classification, subjects with following fracture type:
- a. Pertrochanteric (31-A1 and 31-A2)
- b. Intertrochanteric (31-A3)
- c. Trochanteric area (31-A1/A2/A3) with diaphyseal extension
- 4) Subject must be comfortable with speaking and understanding questions and responses in an available translated language for patient reported outcomes (PROs)

5.2 Exclusion criteria

Subjects who meet any of the following criteria will be excluded from the study:

- 1) Subject does not provide voluntary consent to participate in the study.
- 2) The subject is a woman who is pregnant or lactating
- 3) Fractures where the operative treatment will occur more than three weeks after the primary injury
- 4) Patients with femoral head fractures and femoral neck fractures (AO classification 31-B and 31-C)

- 5) Pathological fracture (e.g., primary or metastatic tumor)
- 6) Serious soft tissue injury, judged by the investigator, will impact the union of the fracture, combined vascular injury, and combined osteofascial compartment syndrome.
- 7) Multiple systemic injuries judged by researchers not suitable for enrollment, or orthopaedic fractures in other bones at three or more sites
- 8) Revision surgeries (for example, due to malunion, nonunion or infection)
- 9) Concurrent medical conditions judged by researchers not suitable for enrollment, such as: diabetes, metabolic bone disease, post-polio syndrome, poor bone quality, prior history of poor fracture healing, etc.
- 10) Patients with anaesthetic and surgical contraindications
- 11) Patents known to be allergic to implant components
- 12) Patients who are currently using chemotherapeutics or accepting radiotherapy, use systematically corticosteroid hormone or growth factor, or long-term use sedative hypnotics (continuous use over 3 months) or non-steroidal anti-inflammatory drugs (continuous use over 3 months)
- 13) Intemperance judged by researchers not suitable for enrollment (e.g., excessive daily drinking or smoking, drug abuse);
- 14) Patients participated into other clinical trial in the previous 3 months;
- 15) Patients with bad compliance judged by researchers and cannot complete the trial according to the study plan, such as schizophrenia and dementia.

6. General Statistical Considerations

6.1 Study hypothesis

The primary endpoint analysis will be to demonstrate that the investigational device (TFNA) is non-inferior to the control device (PFNA-II) based on the fracture union rates at the 24 week follow-up visit. Non-inferiority test will be conducted based on a one-sided 97.5% confidence interval for the difference in the fracture union rate at 24 weeks between the study group and the control group.

The primary hypothesis is that, at 24 weeks after surgery, the investigational device (TFNA) is non-inferior to the control device (PFNA-II) based on the individual patient fracture union rate. Non-inferiority is defined by a test with a two sided 5% type I error and a 10% "margin of non-inferiority".

The study's null and alternative hypotheses are as follows:

$$\begin{split} H_o: \mathbf{P}_{\text{PFNA-II}} - \mathbf{P}_{\text{TFNA}} \geq 10\% \\ H_a: \mathbf{P}_{\text{PFNA-II}} - \mathbf{P}_{\text{TFNA}} < 10\% \end{split}$$

Where, $P_{PFNA-II}$ represents the fracture union rate among those receiving PFNA-II implant and P_{TFNA} denotes the fracture union rate among the recipients of TFNA.

Decision Criterion: The decision will be made to reject the null hypothesis H_0 and conclude the alternative hypothesis H_a if the one-sided 97.5% confidence interval for the difference in the fracture union rates between the control group and the study group is less than the margin of non-inferiority, 10%.

6.2 Sample size calculation

The sample size calculation is determined based on the primary endpoint using PROC POWER in SAS software version 9.3. It assumes that the fracture union rate at 24 weeks after surgery in the TFNA group would be equivalent to that of the PFNA-II group, and a common fracture union rate is approximately 95% or greater based on the literature review. With a non-inferiority margin of 0.10 and a power of 80%, this implies a sample size of 75 for the TFNA and of 75 for PFNA-II surgery groups, respectively. The sample size will be increased to 188 (94 per group) to accommodate potential 20% attrition.

The sample size applies to patients enrolled, randomized, and actually treated. Some patients who enroll in a study and are randomized may not be ultimately treated for various reasons. Patient enrollment and randomization will continue until the proposed sample size for treated patients is complete.

6.3 Analysis population

Full Analysis Set (FAS): The set of subjects determined following the intent-totreat (ITT) principle refers to the data set constituted by all subjects who participate in the randomized study and receive the investigational product (implant) (i.e., ITT population defined in the protocol).

Per Protocol Set (PPS): Refers to the subgroup of treatment population who completes the trial and excluded the population that seriously violates the protocol (which means that study subjects violating the inclusion criteria or meeting exclusion criteria, loss to follow-up during the trial, cross enrollment, out-of-specification use of investigational products, out-of-window time, etc.).

Safety Set (SS): Set of all subjects who participate in the study and use the investigational products and undergo at least one safety evaluation after baseline. (The definitions of SS and FAS are the same. Therefore, SS is not defined separately).

Actual Treatment Set (ATS): All patients who participate in the randomized grouping, complete the trial, actually receive the scheduled treatment in the study (not necessarily consistent with the results of randomized grouping) and do not seriously violates the protocol. On the basis of PPS, only cross-enrolled patients are included, but they are then grouped and analyzed according to their actual treatment, i.e., the actual treatment set is formed.

The primary efficacy analysis will be based on FAS, PPS and ATS (if applicable). All baseline demographic data and secondary efficacy indicator analysis will be performed on the basis of FAS, and the safety evaluation will be performed on the basis of FAS.

6.4 Detailed rules for determination of analysis population set and flow chart

- (1) No investigational device is implanted: Subjects obtain random numbers but do not use any study-related treatment (implantation study group, control group or third party products);
- (2) Violation of inclusion and exclusion criteria: The subjects do not meet the inclusion criteria or meet the exclusion criteria set in the study protocol, and the violation of this protocol will seriously affect the results of primary efficacy endpoints; the sponsor, investigators and statisticians will jointly determine through a blind review meeting whether the protocol violation will seriously affect the results of primary efficacy endpoints;
- (3) Loss to follow-up during the trial: Subjects are unable to obtain the fracture union rate 24 weeks after the primary endpoint surgery;
- (4) Cross enrollment: Subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;
- (5) Out-of-window time: The difference between the follow-up date at 24 weeks after primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and the violation of this protocol may seriously affect the results of primary efficacy endpoints; the sponsor, investigators and statisticians will jointly determine through a blind review meeting whether the protocol violation will seriously affect the results of primary efficacy endpoints;
- (6) Out-of-specification use of investigational products: The specifications of the device implanted in the subject are not within the specification range specified in the study protocol;
- (7) Use of third party products: The subjects randomly assigned to the study group or the control group use third party products;

(8) FAS = Number of subjects enrolled in the trial - Number of subjects not implanted with any investigational device;

PPS = FAS - Number of subjects who seriously violate the study protocol;

ATS = PPS + Number of cross-enrolled subjects alone; ATS will be displayed if subjects are cross-enrolled in the trial, while ATS will not be displayed if no cross-enrollment occurs.

Number of subjects who seriously violate the study protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Out-of-window time + Out-of-specification use of investigational products + Use of third party products;

The priority of serious violations from study protocol: Loss to follow-up during the trial, cross enrollment, use of third party products, violation of inclusion and exclusion criteria, out-of-specification use of investigational products, out-ofwindow time; if the subjects meets the above two or more serious violations, the violations will be classified by priority;

Serious violations from study protocol in the statistical table can be listed according to the actual situation of the data. If the number of subjects who exceed the time window in both the study group and the control group is 0, then such information may not be shown in the table. Meanwhile, the list of subjects who are not implanted with any investigational device or have serious violations from study protocol will be provided, including site number, random number, gender, age, type, reason, FAS, PPS and ATS.




Figure 1 Flow chart for determination of analysis population data sets

6.5 Missing values, abnormal values and outlying values

For possible missing data in the study process, the missing of primary efficacy endpoints will be carried forward only in principle during the analysis. LOCF (Last Observation Carry Forward) was used as sensitivity analysis for the missing of primary efficacy endpoints. That is, the last observed value is used to replace the missing value. In the sensitivity analysis of the LOCF, the last observed value is "Nonunion of fracture " unless the fracture union is definitive. Other missing indicators will not be carried forward and will be directly analyzed based on the actually observed data. Error and unreasonable data will be processed in the data cleaning process before statistical analysis. For withdrawal of subjects, this part of patient information will still be included in the final statistical analysis. Specific reasons for discontinuation or withdrawal of all patients will be explained in detail in the statistical report, and the missing primary endpoint due to early withdrawal will be analyzed according to the above strategy for processing missing values.

If the date (MMDDYYYY) of collection (non-CEC review data) during the trial is filled in with "UK" or "NA", no treatment will be done.

6.6 Significant level and statistical analysis software

For the primary endpoint, statistical analysis will be performed at the one-sided 0.025 significance level (corresponding to the one-sided confidence limit of the 95% confidence interval). For other endpoints, all statistical analysis will be performed at the two-sided 0.05 significance level (except for special instructions). SAS[®] 9.4 statistical software will be used for statistical analysis.

6.7 Site merging principle

This trial is to be conducted simultaneously in multiple clinical trial institutions, and the actual number of subjects successfully included in each site will vary. In order to avoid the influence of too few actual number of subjects successfully enrolled in the site on the stability and reliability of the primary endpoint analysis results, the sites with the actual number of subjects successfully enrolled less than 10 will be merged. According to previous experience and reference, site merging generally adopts the following two methods:

- Sort the sites with the number of subjects actually enrolled less than 10 according to the site number, and merge the sites directly until the number of subjects in the sites is ≥10 after merging;
- (2) Merge the sites according to the principle of geographical proximity, and the number of subjects in the sites should be ≥ 10 after merging;

The site merging principle adopted in the statistical analysis will be further determined by the sponsor, the investigator and the statistician through a blind review meeting.

7. Statistical Analysis Indicators and Statistical Analysis Methods

7.1 Demographic indicators and other baseline indicators

Demographic data include gender, age, height, weight and BMI; other baseline indicators include the subject's medical history, SF-12v2 questionnaire, EQ-5D questionnaire and preoperative fracture status.

Where:

Age = (Date of informed consent - Date of birth)/365.25;

BMI = Body weight $(kg)/(\text{Height }(m))^2$.

The indicators in this part are mainly descriptive. Enumeration data are described by frequency and composition ratio, while measurement data are described by mean, standard deviation, median, quartile, maximum and minimum. The likelihood ratio Chi-square test will be used to compare the enumeration data between groups. Fisher's exact probability test will be used when the theoretical frequency in the fourfold table is less than 5.

7.2 Intraoperative information

The intraoperative information includes the subject's operation time, blood loss volume, blood transfusion volume, investigational device use, intraoperative fracture, etc.

The indicators in this part are mainly descriptive. Statistical analysis methods are the same as those in 7.1.

7.3 Primary endpoint

The primary endpoint is the fracture union rate 24 weeks after surgery.

Fracture union success is a composite endpoint; in order for an individual subject's surgery implanted with TFNA or PFNA-II to be considered successful he/she must satisfy all of the following criteria:

- 1. No focal tenderness or lengthwise percussion pain, or abnormal movement
- 2. The frontal/lateral X-ray examination shows the vague or no fracture gap, or the continuous callus passing across the fracture line
- 3. No deformation or breakage is found in the investigational product

Calculation principle: Based on the postoperative 24-week follow-up of the fracture status and the X-ray examination results of the fracture site, the calculation principle is as follows:

- 1. It is determined as 'Yes' when the focal tenderness, lengthwise percussion pain and abnormal activity at the postoperative 24-week follow-up of the fracture are filled as 'NA', 'NA' and 'No', respectively;
- 2. It is determined as 'Yes' when the X-ray examination at the fracture site 24 weeks after surgery shows that the fracture line is 'vague' or 'disappeared'; or that the frontal/lateral X-ray examination shows the continuous callus passing across the fracture line is filled as 'Yes';
- ③. It is determined as 'Yes' when the X-ray examination at the fracture site 24 weeks after surgery shows that the implant is filled as 'good';

If (1), (2) and (3) are determined as 'Yes', then the successful fracture union 24 weeks after surgery is determined as 'Yes'; if one of them is missing, it is determined as missing, that is, 'loss to follow-up during the trial'; others are determined as 'No';

For the primary endpoint, the analysis bases on the actual data (except missing data). LOCF (Last Observation Carry Forward) was used as sensitivity analysis for the missing of primary efficacy endpoints. The below 2 analysis tests will be used for the above analysis, and estimates of the differences in efficacy between the groups and bilateral two-sided 95% confidence interval will be given:

(1) CMH chi-square test with adjusted central effects;

Calculation method for non – inferiority P value:

Se=(Rate difference 95% upper limit of confidence interval - Rate difference 95% low limit of confidence interval)/2/ probit (1-0.05/2);

Z=(Investigational group-control group of difference in fracture union rates- non-inferiority margin)/Se;

P value=1-probnorm(Z);

(2) Continuous correction Newcombe-Wilson for non-adjusted central;

The result from test (1) will used for the primary analysis result, the result from test (2) will be used as sensitivity analysis result. If the lower limit of the bilateral two-sided 95% confidence interval on differences in efficacy between the study group and the control group (equal to the lower limit of unilateral 95% confidence interval) is greater than -10%, it can be considered that the investigational product is not inferior to the control product

If the actual study results show that other baseline variables (such as age and gender) are significantly different between the study group and the control group, it will be fully communicated to the investigator in the data analysis stage. Based on the results of univariate analysis for baseline variables and primary endpoint, previous literature references and the clinical expert experience, the indicators affecting the primary endpoint to cause imbalance between groups, i.e., confounding factors, will be further specified. These indicators will be considered into the generalized linear model for correction and included into the sensitivity analysis of the primary endpoint analysis.

7.4 Secondary endpoints

Secondary endpoints include the safety and effectiveness results, imaging outcomes and adverse events.

(1) Adverse events (type and frequency) for all adverse events will be compared for the study and control groups

Calculation principle: Based on the collected adverse events in the CRF, if the subject has had at least one adverse event, it will be regarded as 'Yes'; otherwise, it will be 'No'.

The indicators in this part are mainly descriptive. Statistical analysis methods are the same as those in 7.1.

(2) 24-week revision rate, where revision is defined as any component removal for any reason.

Calculation principle: Based on the collected adverse events in the CRF, if the measure taken for the implant is filled as "Revision" and the difference between the date of occurrence of the event and the date of the operation is \leq 196 days, the revision is determined as "Yes"; if postoperative 24-week follow-up is failed, it is determined as "Missing"; others are determined as 'No';

The indicators in this part are mainly descriptive. Statistical analysis methods are the same as those in 7.1.

(3) 24-week re-operation rate, where re-operation is defined as secondary operation of the fracture site for any reason.

Calculation principle: According to the AEs in CRF. If AE "re-operation" site collected in the CRF and occurrence of the event and the date of the operation is \leq 196 days, it is determined as 'Yes'; if postoperative 24-week follow-up is failed, it is determined as 'Missing'; others are determined as 'No'.

The indicators in this part are mainly descriptive. Statistical analysis methods are the same as those in 7.1.

- (4) Clinical outcomes
- ➤ SF-12
- Harris Hip Score
- ► EQ-5D

Calculation principle for SF-12 Score:

SF-12 v2 Questionnaire (each item consists of 8 parts: body functions, physical conditions, body pain, general health, mental health, emotional conditions, social functions and vitality) and general physical and mental health assessment.

Calculation principle: SF-12 scores will be calculated by special software, and statistical analysis will be performed using "_NBS" variable.

The indicators in this part are mainly descriptive. The descriptive analysis results of the SF-12 score and the change from baseline at each follow-up will be given. The statistical analysis method is the same as 7.1. At the same time, the 95% confidence interval of the mean value of change value from each group, the

difference between groups and its 95% confidence interval are also provided.

Calculation principle for Harris hip score:

Total Harris hip score: It can be calculated by adding the scores of each sub-item.

(I) Regarding the complaint pain score (44 points in total), the specific points are as follows:

None, or ignores it (44 points)

Slight, occasional, no compromise in activities (40 points)

Mild pain, no effect on average activities (30 points)

Moderate pain, tolerable (20 points)

Marked pain, serious limitation of activities (10 points)

Totally disabled, crippled, pain in bed, bedridden (0 point)

(II) Function score (47 points in total): Gait score (33 points) + daily life score (14 points), the specific points are as follows:

Gait score (33):

- Support: None (11 points); Cane for long walks (7 points); Cane most of time (5 points); One crutch (3 points); Two canes (2 points); Two crutches or not able to walk (0 point)
- Distance Walked: Unlimited (11 points); Six blocks (30 minutes) (8 points); Two or three blocks (10 or 15 minutes) (5 points); Indoors only (2 points); Bed and chair only (0 point)
- ③ Limp: None (11 points); Slight (8 points); Moderate (5 points); Severe or unable to walk (0 point)

Daily life score (14 points):

- Put on Shoes and Socks: With ease (4 points); With difficulty (2 points); Unable (0 point)
- 2 Stairs: Normally without using a railing (4 points); Normally using a railing (2 points); In any manner (1 point); Unable to do stairs (0 point)
- ③ Enter public transportation: Yes (bus) (1 point); No (bus) (0 point)
- ④ Sitting: Comfortably in ordinary chair for one hour (5 points); On a high chair for 30 minutes (3 points); Unable to sit comfortably in any chair (0 point)

(III) Physical sign score (4 points in total), the specific points are as follows:

Whether all of the following conditions exist: (Less than 30° fixed flexion contracture; Less than 10° fixed internal rotation in extension; Less than 10° fixed

abduction; Limb length discrepancy less than 3.2 cm (1.5 inches);)

Yes (4 points), No (0 point)

- (IV) Physical examination score: Score result = The sum of A, B, C and D divided by 20; the specific points are as follows (refer to computation rule for Harris Hip Score in <u>http://www.orthopaedicscores.com</u>, which was approved by the Journal of Bone & Joint Surgery):
- A. Total flexion: None (0 point), 0 >8 (0.4 points), 8 >16 (0.8 points), 16 >24 (1.2 points), 24 >32 (1.6 points), 32 >40 (2 points), 40 >45 (2.25 points), 45 >55 (2.55 points), 55 >65 (2.85 points), 65 >70 (3 points), 70 >75 (3.15 points), 75 >80 (3.3 points), 80 >90 (3.6 points), 90 >100 (3.75 points), 100 >110 (3.9 points);
- B. Total abduction: None (0 point), 0 >5 (0.2 points), 5 >10 (0.4 points), 10 >15 (0.6 points), 15 >20 (0.65 points);
- C. Total external rotation: None (0 point), $0 \ge 5$ (0.1 point), $5 \ge 10$ (0.2 points), $10 \ge 15$ (0.3 points);

Total internal rotation: None (0 point), 0 > 5 (0.05 points), 5 > 10 (0.1 points), 10 > 15 (0.15 points);

Total Harris hip score: It can be calculated by adding the scores of the above four sub-items.

- If a sub-score is missing then the total score cannot be calculated
- If total score exceeds 100 then it should be forced to be 100

The indicators in this part are mainly descriptive. The descriptive analysis results of Harris hip score at each follow-up will be given. The statistical analysis method is the same as 7.1.

EQ-5D questionnaire:

Based on the EQ-5D questionnaire collected in the CRF, the analysis results of subjects' health status and health index are given. The analysis results 12 and 24 weeks after surgery are given, respectively.

Calculation principle:

Health status is measured in five dimensions (activity level, self-care, daily activities, pain/discomfort, anxiety/depression). Each dimension contains five levels: no difficulty, mild difficulty, moderate difficulty, severe difficulty, and extreme difficulty (marked 1-5). The health status of each subject is determined by arranging the five dimensions of each subject.

Health index is calculated by 《EQ-5D-5L_Crosswalk_Index_Value_Calculator.v2.xls》. Medical Research & Biometrics Center, National Version No.: V1.0 21/129 The indicators in this part are mainly descriptive. A descriptive analysis of each follow-up health index and changes relative to baseline will be presented. Statistical analysis methods are the same as those in 7.1.

(5) Radiographs: incidence of complications such as loosening or cut-out that require reoperation or revision.

Calculation principle: Based on the adverse events collected in the CRF. If the measure taken for the implant is filled as "Revision" or AE "re-operation" collected in the CRF, it is determined as 'Missing'; otherwise are determined as 'No'

The indicators in this part are mainly descriptive. Statistical analysis methods are the same as those in 7.1.

7.5 Follow-up data

The follow-up data include the frontal/lateral X-ray examination of fracture sites 1 week, 6 weeks, 12 weeks and 24 weeks after surgery, SF-12v2 health assessment scale, EQ5D and Harris hip score.

For indicators related to follow-up data, descriptive analysis is mainly performed. Statistical analysis methods are the same as those in 7.1.

7.6 Laboratory examinations

Laboratory test indicators include complete blood count and blood biochemical test. Blood test includes white blood cell (WBC), neutrophil percentage, red blood cell (RBC), hemoglobin, platelet, international normalized ratio (INR) and activated partial thromboplastin time (APTT); blood biochemical test includes alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), cholesterol (CHOL), triglyceride (TRIG), creatinine (CREA), blood urea nitrogen (BUN), urea (UREA), uric acid (UA), low density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), blood glucose (GLU), C-reactive protein (CRP) and hypersensitive CRP.

As for the laboratory examination indicators, the outcomes immediately after surgery relative to the preoperative conditions will be given. There are mainly five cases listed, including "Normal \rightarrow Abnormal (with clinical significance)", "Normal \rightarrow Abnormal (without clinical significance)", "Normal \rightarrow Normal", "Abnormal \rightarrow Abnormal"; the descriptive analysis method is mainly adopted. Statistical analysis methods are the same as those in 7.1. Meanwhile, the list of subjects presenting "Normal \rightarrow Abnormal (with clinical significance)" will be given, including laboratory examination indicators, site number, random number, group, age, gender, and laboratory indicator test values before surgery and immediately after surgery.

7.7 Concomitant medication, adverse events (AEs) or serious adverse events

(SAEs)

For concomitant medication, the subject's concomitant medication is provided in the form of a list.

The AEs and investigational device-related AEs in subjects will be tabulated and summarized, respectively. The list of subjects reported with AEs/ investigational device-related AEs includes site number, random number, group, age, gender, name of AE (SOC code), name of AE (PT code), time of postoperative occurrence (day), remission time (day), severity, measures taken, outcome, correlation with surgery, correlation with investigational device, withdrawal from the trial due to AEs, whether it is unanticipated adverse device effect (UADE), device failure or SAE.

Investigational device-related AEs refer to those "definitely related", "probably related" and "possibly related" with the investigational device;

Time of postoperative occurrence (day) = Date of occurrence of AE - Date of surgery,

Remission time (day) = End date of AE - Date of occurrence of AE.

The summary form will list the total number of cases of AEs/investigational device-related AEs, the total number of subjects suffering from AEs/investigational device-related AEs.

Wherein, the total case of AEs refers to the number of subjects suffering from AEs, and the AEs occur in the subject at least one time, which is considered as "Yes";

Statistical analysis of the severity of adverse events, the relationship with the study device and the relationship with the surgery was performed. If multiple adverse events occurred in a patient, the analysis was performed with the most severe or highest correlation.

The SAEs and investigational device-related SAEs in subjects will be tabulated and summarized, respectively; such data will be presented in the same form as AEs. The list of subjects reported with SAEs/investigational device-related SAEs includes site number, random number, group, age, gender, name of SAE (SOC code), name of SAE (PT code), time of postoperative occurrence (day), remission time (day), severity, outcome, correlation with surgery, correlation with investigational device and SAE.

The list and summary of UADEs in subjects will be presented respectively in the same form as AEs.

The calculation method of the time of postoperative occurrence (day) and remission time (day), the presentation of the summary form and the statistical principle are the same as those for AEs.

Randomization (N=XXX) Control group Study group (N=XXX) (N=XXX) No investigational device is implanted Study group: N₁=XXX Control group: N₂=XXX FAS FAS (N=XXX) (N=XXX) Serious protocol violation (Study group: N1=XXX, Control group: N₂=XXX): 1. Loss to follow-up during the trial (N1=XXX, N₂=XXX) 2. Cross enrollment (N1=XXX, N2=XXX) 3. Use of third party products (N₁=XXX, N₂=XXX) 4. Violation of inclusion and exclusion criteria (N1=XXX, N2=XXX) PPS PPS (N=XXX) (N=XXX) ATS ATS (N=XXX) (N=XXX)

8. Generation of Statistical Graphs, Tables and Lists

Figure 1 Flow chart for determination of analysis population data sets

Indicator	Study group	Control group
Randomization	XXX (XX.X%)	XXX (XX.X%)
No investigational device is implanted	XXX (XX.X%)	XXX (XX.X%)
Serious protocol violation		
Violation of inclusion and exclusion criteria	XXX (XX.X%)	XXX (XX.X%)
Loss to follow-up during the trial	XXX (XX.X%)	XXX (XX.X%)
Cross enrollment	XXX (XX.X%)	XXX (XX.X%)
Use of third party products	XXX (XX.X%)	XXX (XX.X%)
Out-of-specification use of investigational products	XXX (XX.X%)	XXX (XX.X%)
Out-of-window time	XXX (XX.X%)	XXX (XX.X%)
FAS	XXX (XX.X%)	XXX (XX.X%)
PPS	XXX (XX.X%)	XXX (XX.X%)
ATS	XXX (XX.X%)	XXX (XX.X%)

Table 1Determination of analysis population

Notes: 1. FAS = Number of subjects enrolled randomly - Number of subjects not implanted with any investigational device;

2. Number of subjects who seriously violate the protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Use of third party products + Out-of-specification use of investigational products + Out-of-window time;

3. PPS = FAS - Number of subjects who seriously violate the protocol; ATS = PPS + Number of cross-enrolled subjects alone;

4. No investigational device is implanted means that the subject has been given a random number but has not received any study-related treatment;

Loss to follow-up during the trial refers to the situation in which the fracture union rate 24 weeks after the primary endpoint surgery is not available;

Cross enrollment refers to the situation in which subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;

Out-of-specification use of investigational products refers to the situation in which the specification of the device implanted in the subject is not within the specification range specified in the study protocol;

Use of third party products refers to the situation in which the subjects randomly assigned to the study group or the control group use third party products;

Out-of-window time refers to the situation in which the difference between the follow-up date at 24 weeks after subjects have received the primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and this protocol violation may seriously affect the results of primary efficacy endpoints;

Table 2List of subjects who withdrawal the informed consent or
seriously violate the protocol

Site No.	Random No.	Group	Gender	Age	Туре	Reason	FAS	PPS	ATS
XXX	XXX	XXX	XXX	XXX					
XXX	XXX	XXX	XXX	XXX					

Note: If the subject is included in FAS, PPS and ATS, mark with " $\sqrt{}$ "; if the subject is not included in FAS, PPS and ATS, mark with " \times ".

-

_

Site No.	Random No.	Group	Gender	Age	Туре	AE/SAE related or not	Withdrawal of subjects from the trial or not
XXX	XXX	XXX	XXX	XXX			
XXX	XXX	XXX	XXX	XXX			

Table 3 List of subjects who violate the protocol (CRF collection)

Indicator	Study group	Control group
Randomization	XXX (XX.X%)	XXX (XX.X%)
No investigational device is implanted	XXX (XX.X%)	XXX (XX.X%)
Serious protocol violation		
Violation of inclusion and exclusion criteria	XXX (XX.X%)	XXX (XX.X%)
Loss to follow-up during the trial	XXX (XX.X%)	XXX (XX.X%)
Cross enrollment	XXX (XX.X%)	XXX (XX.X%)
Use of third party products	XXX (XX.X%)	XXX (XX.X%)
Out-of-specification use of investigational products	XXX (XX.X%)	XXX (XX.X%)
Out-of-window time	XXX (XX.X%)	XXX (XX.X%)
FAS	XXX (XX.X%)	XXX (XX.X%)
PPS	XXX (XX.X%)	XXX (XX.X%)
ATS	XXX (XX.X%)	XXX (XX.X%)

Table 4Determination of analysis population in Beijing JishuitanHospital

Notes: 1. FAS = Number of subjects enrolled randomly - Number of subjects not implanted with any investigational device;

2. Number of subjects who seriously violate the protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Use of third party products + Out-of-specification use of investigational products + Out-of-window time;

3. PPS = FAS - Number of subjects who seriously violate the protocol; ATS = PPS + Number of cross-enrolled subjects alone;

4. No investigational device is implanted means that the subject has been given a random number but has not received any study-related treatment;

Loss to follow-up during the trial refers to the situation in which the fracture union rate 24 weeks after the primary endpoint surgery is not available;

Cross enrollment refers to the situation in which subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;

Out-of-specification use of investigational products refers to the situation in which the specification of the device implanted in the subject is not within the specification range specified in the study protocol;

Use of third party products refers to the situation in which the subjects randomly assigned to the study group or the control group use third party products;

Out-of-window time refers to the situation in which the difference between the follow-up date at 24 weeks after subjects have received the primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and this protocol violation may seriously affect the results of primary efficacy endpoints;

Indicator	Study group	Control group
Randomization	XXX (XX.X%)	XXX (XX.X%)
No investigational device is implanted	XXX (XX.X%)	XXX (XX.X%)
Serious protocol violation		
Violation of inclusion and exclusion criteria	XXX (XX.X%)	XXX (XX.X%)
Loss to follow-up during the trial	XXX (XX.X%)	XXX (XX.X%)
Cross enrollment	XXX (XX.X%)	XXX (XX.X%)
Use of third party products	XXX (XX.X%)	XXX (XX.X%)
Out-of-specification use of investigational products	XXX (XX.X%)	XXX (XX.X%)
Out-of-window time	XXX (XX.X%)	XXX (XX.X%)
FAS	XXX (XX.X%)	XXX (XX.X%)
PPS	XXX (XX.X%)	XXX (XX.X%)
ATS	XXX (XX.X%)	XXX (XX.X%)

Table 5 **Determination of analysis population in Peking University Third** Hospital

Notes:

1. FAS = Number of subjects enrolled randomly - Number of subjects not implanted with any investigational device;

2: Number of subjects who seriously violate the protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Use of third party products + Out-of-specification use of investigational products + Out-of-window time;

3. PPS = FAS - Number of subjects who seriously violate the protocol; ATS = PPS + Numberof cross-enrolled subjects alone;

4. No investigational device is implanted means that the subject has been given a random number but has not received any study-related treatment;

Loss to follow-up during the trial refers to the situation in which the fracture union rate 24 weeks after the primary endpoint surgery is not available;

Cross enrollment refers to the situation in which subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;

Out-of-specification use of investigational products refers to the situation in which the specification of the device implanted in the subject is not within the specification range specified in the study protocol;

Use of third party products refers to the situation in which the subjects randomly assigned to the study group or the control group use third party products;

Out-of-window time refers to the situation in which the difference between the follow-up date at 24 weeks after subjects have received the primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and this protocol violation may seriously affect the results of primary efficacy endpoints;

Indicator	Study group	Control group
Randomization	XXX (XX.X%)	XXX (XX.X%)
No investigational device is implanted	XXX (XX.X%)	XXX (XX.X%)
Serious protocol violation		
Violation of inclusion and exclusion criteria	XXX (XX.X%)	XXX (XX.X%)
Loss to follow-up during the trial	XXX (XX.X%)	XXX (XX.X%)
Cross enrollment	XXX (XX.X%)	XXX (XX.X%)
Use of third party products	XXX (XX.X%)	XXX (XX.X%)
Out-of-specification use of investigational products	XXX (XX.X%)	XXX (XX.X%)
Out-of-window time	XXX (XX.X%)	XXX (XX.X%)
FAS	XXX (XX.X%)	XXX (XX.X%)
PPS	XXX (XX.X%)	XXX (XX.X%)
ATS	XXX (XX.X%)	XXX (XX.X%)

Table 6Determination of analysis population in Chinese PLA General
Hospital

Notes: 1. FAS = Number of subjects enrolled randomly - Number of subjects not implanted with any investigational device;

2: Number of subjects who seriously violate the protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Use of third party products + Out-of-specification use of investigational products + Out-of-window time;

3. PPS = FAS - Number of subjects who seriously violate the protocol; ATS = PPS + Number of cross-enrolled subjects alone;

4. No investigational device is implanted means that the subject has been given a random number but has not received any study-related treatment;

Loss to follow-up during the trial refers to the situation in which the fracture union rate 24 weeks after the primary endpoint surgery is not available;

Cross enrollment refers to the situation in which subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;

Out-of-specification use of investigational products refers to the situation in which the specification of the device implanted in the subject is not within the specification range specified in the study protocol;

Use of third party products refers to the situation in which the subjects randomly assigned to the study group or the control group use third party products;

Out-of-window time refers to the situation in which the difference between the follow-up date at 24 weeks after subjects have received the primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and this protocol violation may seriously affect the results of primary efficacy endpoints;

Table 7

Hospital of Zhejiang University School of Medicine		
Indicator	Study group	Control group
D 1		

Determination of analysis nonulation in the Second Affiliated

Indicator	Study group	Control group
Randomization	XXX (XX.X%)	XXX (XX.X%)
No investigational device is implanted	XXX (XX.X%)	XXX (XX.X%)
Serious protocol violation		
Violation of inclusion and exclusion criteria	XXX (XX.X%)	XXX (XX.X%)
Loss to follow-up during the trial	XXX (XX.X%)	XXX (XX.X%)
Cross enrollment	XXX (XX.X%)	XXX (XX.X%)
Use of third party products	XXX (XX.X%)	XXX (XX.X%)
Out-of-specification use of investigational	XXX (XX.X%)	XXX (XX.X%)
products		
Out-of-window time	XXX (XX.X%)	XXX (XX.X%)
FAS	XXX (XX.X%)	XXX (XX.X%)
PPS	XXX (XX.X%)	XXX (XX.X%)
ATS	XXX (XX.X%)	XXX (XX.X%)

Notes: 1. FAS = Number of subjects enrolled randomly - Number of subjects not implanted with any investigational device;

2: Number of subjects who seriously violate the protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Use of third party products + Out-of-specification use of investigational products + Out-of-window time;

3. PPS = FAS - Number of subjects who seriously violate the protocol; ATS = PPS + Number of cross-enrolled subjects alone;

4. No investigational device is implanted means that the subject has been given a random number but has not received any study-related treatment;

Loss to follow-up during the trial refers to the situation in which the fracture union rate 24 weeks after the primary endpoint surgery is not available;

Cross enrollment refers to the situation in which subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;

Out-of-specification use of investigational products refers to the situation in which the specification of the device implanted in the subject is not within the specification range specified in the study protocol;

Use of third party products refers to the situation in which the subjects randomly assigned to the study group or the control group use third party products;

Out-of-window time refers to the situation in which the difference between the follow-up date at 24 weeks after subjects have received the primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and this protocol violation may seriously affect the results of primary efficacy endpoints;

Indicator	Study group	Control group
Randomization	XXX (XX.X%)	XXX (XX.X%)
No investigational device is implanted	XXX (XX.X%)	XXX (XX.X%)
Serious protocol violation		
Violation of inclusion and exclusion criteria	XXX (XX.X%)	XXX (XX.X%)
Loss to follow-up during the trial	XXX (XX.X%)	XXX (XX.X%)
Cross enrollment	XXX (XX.X%)	XXX (XX.X%)
Use of third party products	XXX (XX.X%)	XXX (XX.X%)
Out-of-specification use of investigational products	XXX (XX.X%)	XXX (XX.X%)
Out-of-window time	XXX (XX.X%)	XXX (XX.X%)
FAS	XXX (XX.X%)	XXX (XX.X%)
PPS	XXX (XX.X%)	XXX (XX.X%)
ATS	XXX (XX.X%)	XXX (XX.X%)

Table 8Determination of analysis population in Shanghai General
Hospital

Notes: 1. FAS = Number of subjects enrolled randomly - Number of subjects not implanted with any investigational device;

2: Number of subjects who seriously violate the protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Use of third party products + Out-of-specification use of investigational products + Out-of-window time;

3. PPS = FAS - Number of subjects who seriously violate the protocol; ATS = PPS + Number of cross-enrolled subjects alone;

4. No investigational device is implanted means that the subject has been given a random number but has not received any study-related treatment;

Loss to follow-up during the trial refers to the situation in which the fracture union rate 24 weeks after the primary endpoint surgery is not available;

Cross enrollment refers to the situation in which subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;

Out-of-specification use of investigational products refers to the situation in which the specification of the device implanted in the subject is not within the specification range specified in the study protocol;

Use of third party products refers to the situation in which the subjects randomly assigned to the study group or the control group use third party products;

Out-of-window time refers to the situation in which the difference between the follow-up date at 24 weeks after subjects have received the primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and this protocol violation may seriously affect the results of primary efficacy endpoints;

Southern wiedical Oniversity		
Indicator	Study group	Control group
Randomization	XXX (XX.X%)	XXX (XX.X%)
No investigational device is implanted	XXX (XX.X%)	XXX (XX.X%)
Serious protocol violation		
Violation of inclusion and exclusion criteria	XXX (XX.X%)	XXX (XX.X%)
Loss to follow-up during the trial	XXX (XX.X%)	XXX (XX.X%)
Cross enrollment	XXX (XX.X%)	XXX (XX.X%)
Use of third party products	XXX (XX.X%)	XXX (XX.X%)
Out-of-specification use of investigational products	XXX (XX.X%)	XXX (XX.X%)
Out-of-window time	XXX (XX.X%)	XXX (XX.X%)
FAS	XXX (XX.X%)	XXX (XX.X%)
PPS	XXX (XX.X%)	XXX (XX.X%)
ATS	XXX (XX.X%)	XXX (XX.X%)

Table 9Determination of analysis population in Nanfang Hospital Of
Southern Medical University

Notes: 1. FAS = Number of subjects enrolled randomly - Number of subjects not implanted with any investigational device;

2: Number of subjects who seriously violate the protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Use of third party products + Out-of-specification use of investigational products + Out-of-window time;

3. PPS = FAS - Number of subjects who seriously violate the protocol; ATS = PPS + Number of cross-enrolled subjects alone;

4. No investigational device is implanted means that the subject has been given a random number but has not received any study-related treatment;

Loss to follow-up during the trial refers to the situation in which the fracture union rate 24 weeks after the primary endpoint surgery is not available;

Cross enrollment refers to the situation in which subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;

Out-of-specification use of investigational products refers to the situation in which the specification of the device implanted in the subject is not within the specification range specified in the study protocol;

Use of third party products refers to the situation in which the subjects randomly assigned to the study group or the control group use third party products;

Out-of-window time refers to the situation in which the difference between the follow-up date at 24 weeks after subjects have received the primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and this protocol violation may seriously affect the results of primary efficacy endpoints;

Indicator	Study group	Control group
Randomization	XXX (XX.X%)	XXX (XX.X%)
No investigational device is implanted	XXX (XX.X%)	XXX (XX.X%)
Serious protocol violation		
Violation of inclusion and exclusion criteria	XXX (XX.X%)	XXX (XX.X%)
Loss to follow-up during the trial	XXX (XX.X%)	XXX (XX.X%)
Cross enrollment	XXX (XX.X%)	XXX (XX.X%)
Use of third party products	XXX (XX.X%)	XXX (XX.X%)
Out-of-specification use of investigational products	XXX (XX.X%)	XXX (XX.X%)
Out-of-window time	XXX (XX.X%)	XXX (XX.X%)
FAS	XXX (XX.X%)	XXX (XX.X%)
PPS	XXX (XX.X%)	XXX (XX.X%)
ATS	XXX (XX.X%)	XXX (XX.X%)

Table 10 Determination of analysis population in Affiliated Hospital ofNantong University

Notes: 1. FAS = Number of subjects enrolled randomly - Number of subjects not implanted with any investigational device;

2: Number of subjects who seriously violate the protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Use of third party products + Out-of-specification use of investigational products + Out-of-window time;

3. PPS = FAS - Number of subjects who seriously violate the protocol; ATS = PPS + Number of cross-enrolled subjects alone;

4. No investigational device is implanted means that the subject has been given a random number but has not received any study-related treatment;

Loss to follow-up during the trial refers to the situation in which the fracture union rate 24 weeks after the primary endpoint surgery is not available;

Cross enrollment refers to the situation in which subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;

Out-of-specification use of investigational products refers to the situation in which the specification of the device implanted in the subject is not within the specification range specified in the study protocol;

Use of third party products refers to the situation in which the subjects randomly assigned to the study group or the control group use third party products;

Out-of-window time refers to the situation in which the difference between the follow-up date at 24 weeks after subjects have received the primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and this protocol violation may seriously affect the results of primary efficacy endpoints;

Indicator	Study group	Control group
Randomization	XXX (XX.X%)	XXX (XX.X%)
No investigational device is implanted	XXX (XX.X%)	XXX (XX.X%)
Serious protocol violation		
Violation of inclusion and exclusion criteria	XXX (XX.X%)	XXX (XX.X%)
Loss to follow-up during the trial	XXX (XX.X%)	XXX (XX.X%)
Cross enrollment	XXX (XX.X%)	XXX (XX.X%)
Use of third party products	XXX (XX.X%)	XXX (XX.X%)
Out-of-specification use of investigational products	XXX (XX.X%)	XXX (XX.X%)
Out-of-window time	XXX (XX.X%)	XXX (XX.X%)
FAS	XXX (XX.X%)	XXX (XX.X%)
PPS	XXX (XX.X%)	XXX (XX.X%)
ATS	XXX (XX.X%)	XXX (XX.X%)

Table 11 Determination of analysis population in West China Hospital,Sichuan University

Notes: 1. FAS = Number of subjects enrolled randomly - Number of subjects not implanted with any investigational device;

2: Number of subjects who seriously violate the protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Use of third party products + Out-of-specification use of investigational products + Out-of-window time;

3. PPS = FAS - Number of subjects who seriously violate the protocol; ATS = PPS + Number of cross-enrolled subjects alone;

4. No investigational device is implanted means that the subject has been given a random number but has not received any study-related treatment;

Loss to follow-up during the trial refers to the situation in which the fracture union rate 24 weeks after the primary endpoint surgery is not available;

Cross enrollment refers to the situation in which subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;

Out-of-specification use of investigational products refers to the situation in which the specification of the device implanted in the subject is not within the specification range specified in the study protocol;

Use of third party products refers to the situation in which the subjects randomly assigned to the study group or the control group use third party products;

Out-of-window time refers to the situation in which the difference between the follow-up date at 24 weeks after subjects have received the primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and this protocol violation may seriously affect the results of primary efficacy endpoints;

Table 12 Determination of analysis population in the First AffiliatedHospital of Guangzhou University of Chinese Medicine

Indicator	Study group	Control group
Randomization	XXX (XX.X%)	XXX (XX.X%)
No investigational device is implanted	XXX (XX.X%)	XXX (XX.X%)
Serious protocol violation		
Violation of inclusion and exclusion criteria	XXX (XX.X%)	XXX (XX.X%)
Loss to follow-up during the trial	XXX (XX.X%)	XXX (XX.X%)
Cross enrollment	XXX (XX.X%)	XXX (XX.X%)
Use of third party products	XXX (XX.X%)	XXX (XX.X%)
Out-of-specification use of investigational products	XXX (XX.X%)	XXX (XX.X%)
Out-of-window time	XXX (XX.X%)	XXX (XX.X%)
FAS	XXX (XX.X%)	XXX (XX.X%)
PPS	XXX (XX.X%)	XXX (XX.X%)
ATS	XXX (XX.X%)	XXX (XX.X%)

Notes: 1. FAS = Number of subjects enrolled randomly - Number of subjects not implanted with any investigational device;

2: Number of subjects who seriously violate the protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Use of third party products + Out-of-specification use of investigational products + Out-of-window time;

3. PPS = FAS - Number of subjects who seriously violate the protocol; ATS = PPS + Number of cross-enrolled subjects alone;

4. No investigational device is implanted means that the subject has been given a random number but has not received any study-related treatment;

Loss to follow-up during the trial refers to the situation in which the fracture union rate 24 weeks after the primary endpoint surgery is not available;

Cross enrollment refers to the situation in which subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;

Out-of-specification use of investigational products refers to the situation in which the specification of the device implanted in the subject is not within the specification range specified in the study protocol;

Use of third party products refers to the situation in which the subjects randomly assigned to the study group or the control group use third party products;

Out-of-window time refers to the situation in which the difference between the follow-up date at 24 weeks after subjects have received the primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and this protocol violation may seriously affect the results of primary efficacy endpoints;

Indicator Study group	Control group	
Randomization	XXX (XX.X%)	XXX (XX.X%)
No investigational device is implanted	XXX (XX.X%)	XXX (XX.X%)
Serious protocol violation		
Violation of inclusion and exclusion criteria	XXX (XX.X%)	XXX (XX.X%)
Loss to follow-up during the trial	XXX (XX.X%)	XXX (XX.X%)
Cross enrollment	XXX (XX.X%)	XXX (XX.X%)
Use of third party products	XXX (XX.X%)	XXX (XX.X%)
Out-of-specification use of investigational products	XXX (XX.X%)	XXX (XX.X%)
Out-of-window time	XXX (XX.X%)	XXX (XX.X%)
FAS	XXX (XX.X%)	XXX (XX.X%)
PPS	XXX (XX.X%)	XXX (XX.X%)
ATS	XXX (XX.X%)	XXX (XX.X%)

Table 13 Determination of analysis population in the University of HongKong - Shenzhen Hospital

Notes: 1. FAS = Number of subjects enrolled randomly - Number of subjects not implanted with any investigational device;

2: Number of subjects who seriously violate the protocol = Violation of inclusion and exclusion criteria + Loss to follow-up during the trial + Cross enrollment + Use of third party products + Out-of-specification use of investigational products + Out-of-window time;

3. PPS = FAS - Number of subjects who seriously violate the protocol; ATS = PPS + Number of cross-enrolled subjects alone;

4. No investigational device is implanted means that the subject has been given a random number but has not received any study-related treatment;

Loss to follow-up during the trial refers to the situation in which the fracture union rate 24 weeks after the primary endpoint surgery is not available;

Cross enrollment refers to the situation in which subjects randomly assigned to the study group receive the control products, while subjects randomly assigned to the control group receive the investigational products;

Out-of-specification use of investigational products refers to the situation in which the specification of the device implanted in the subject is not within the specification range specified in the study protocol;

Use of third party products refers to the situation in which the subjects randomly assigned to the study group or the control group use third party products;

Out-of-window time refers to the situation in which the difference between the follow-up date at 24 weeks after subjects have received the primary endpoint surgery and the surgery date do not fall within the range of [140, 196], and this protocol violation may seriously affect the results of primary efficacy endpoints;

Indicator	Study group	Control group	Statistics	P value
Age (years)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Gender				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Male	XXX (XX.X%)	XXX (XX.X%)		
Female	XXX (XX.X%)	XXX (XX.X%)		
Marital status				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Married	XXX (XX.X%)	XXX (XX.X%)		
Unmarried	XXX (XX.X%)	XXX (XX.X%)		
Nationality				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Han nationality	XXX (XX.X%)	XXX (XX.X%)		
Others	XXX (XX.X%)	XXX (XX.X%)		
Job nature				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Manual worker	XXX (XX.X%)	XXX (XX.X%)		
Non-manual worker	XXX (XX.X%)	XXX (XX.X%)		
Retired	XXX (XX.X%)	XXX (XX.X%)		
Unemployed	XXX (XX.X%)	XXX (XX.X%)		
Incompetent	XXX (XX.X%)	XXX (XX.X%)		
Others	XXX (XX.X%)	XXX (XX.X%)		

Table 14 Statistical analysis results of subjects' demographic data

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

3. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

4. Age = (Date of informed consent - Date of birth)/365.25;

	•	•	-	0
Indicator	Study group	Control group	Statistics	P value
Body weight (kg)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)X.XXXX	X.XXXX	
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Height (cm)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
BMI(kg/m^2)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean ± SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX;XX.XX	XX.XX ;XX.XX		

Table 15 Statistical analysis results of subjects' height and body weight

- Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.
 - 2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.
 - 3. BMI= Body weight (kg)/Height (m)2;

Indicator	Study group	Control group	Statistics	P value
Osteoporosis				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Still persist	()			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Malnutrition				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
None	XXX (XX.X%)	XXX (XX.X%)		
Ca	XXX (XX.X%)	XXX (XX.X%)		
Р	XXX (XX.X%)	XXX (XX.X%)		
Protein	XXX (XX.X%)	XXX (XX.X%)		
Fe	XXX (XX.X%)	XXX (XX.X%)		
Others	XXX (XX.X%)	XXX (XX.X%)		
Still persist	. ,			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Anemia				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Still persist				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Hormone deficiency				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
None	XXX (XX.X%)	XXX (XX.X%)		
Medical Research & Biometrics Center, Nati	onal	Version No.: V1.0)	41/129

Table 16Statistical analysis results of subjects' previous and current
medical history

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

Johnson Medical (Shanghai) Co., Ltd.		~	,	42/129
Growth hormone	XXX (XX.X%)	XXX (XX.X%)		
Parathyroid hormone	XXX (XX.X%)	XXX (XX.X%)		
Others	XXX (XX.X%)	XXX (XX.X%)		
Still persist				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Statistical Analysis Plan for Study Evaluating Trochanteric Fixation Nail Advanced (TFNA) of Johnson & Johnson Medical (Shanghai) Co., Ltd.

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Diabetes mellitus				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes (satisfactory control)	XXX (XX.X%)	XXX (XX.X%)		
Yes (unsatisfactory control)	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Allergic history				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Other complications				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Still persist	· · · ·			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Smoke within one year or not	· · · ·			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Number of cigarettes/day	· · · ·			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean ± SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Still persist		,		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Drink within one year or not	. ,	、		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Table 16Statistical analysis results of subjects' previous and current
medical history (continued 1)

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

3. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
ml/day				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX; XX.XX	XX.XX; XX.XX		
Minimum; maximum	XX.XX; XX.XX	XX.XX; XX.XX		
Still persist				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Surgical history				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Table 16Statistical analysis results of subjects' previous and current
medical history (continued 2)

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

3. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
SF-12 score (body functions)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
SF-12 score (physical conditions)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
$Mean \pm SD$	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
SF-12 score (body pain)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
SF-12 score (general health)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
SF-12 score (vitality)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
SF-12 score (social functions)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		

Table 17Statistical analysis results of subjects' preoperative SF-12v2questionnaire

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
SF-12 score (emotional conditions)	<u>Study Group</u>	<u>Control Broup</u>	Statistics	1 vuide
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
SF-12 score (mental health)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean ± SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
SF-12 score (total physical health sco	ore)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean ± SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX;XX.XX	XX.XX ;XX.XX		
SF-12 score (total mental health score	e)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		

Table 17Statistical analysis results of subjects' preoperative SF-12v2
questionnaire (continued)

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

C	uestionnaire			
Indicator	Study group	Control group	Statistics	P value
Activity level				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Walk easily	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to walk	XXX (XX.X%)	XXX (XX.X%)		
Self-care				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Easy to wash or dress independently	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to wash or dress independently	XXX (XX.X%)	XXX (XX.X%)		
Daily activities (such as work, study, house	work, family or ent	ertainment)		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Easy to perform daily activities	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to perform daily activities	XXX (XX.X%)	XXX (XX.X%)		
Pain/discomfort				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Mild pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Moderate pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Severe pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Very severe pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Anxiety/depression				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Mild anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Moderate anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Severe anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Very severe anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		

Table 18 Statistical analysis results of subjects' preoperative EQ-5D questionnaire

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

47/129

3. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

4. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Table 18Statistical analysis results of subjects' preoperative EQ-5D
questionnaire (continued)

Indicator	Study group	Control group	Statistics	P value
Health index				
Number of subjects (Nmiss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

3. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
Limb malformation				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Flexion	XXX (XX.X%)	XXX (XX.X%)		
Shortening	XXX (XX.X%)	XXX (XX.X%)		
Limb malformation and external rotat	tion			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
External rotation < 30°	XXX (XX.X%)	XXX (XX.X%)		
30° < External rotation < 60°	XXX (XX.X%)	XXX (XX.X%)		
External rotation 260°	XXX (XX.X%)	XXX (XX.X%)		
Closed fracture		× ,		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
C 0	XXX (XX.X%)	XXX (XX.X%)		
CI	XXX (XX.X%)	XXX (XX.X%)		
CII	XXX (XX.X%)	XXX (XX.X%)		
C III	XXX (XX.X%)	XXX (XX.X%)		
Open fracture				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
0	Ι	XXX (XX.X%)	XXX (XX.X%)	
O II	XXX (XX.X%)	XXX (XX.X%)		
O III	XXX (XX.X%)	XXX (XX.X%)		
O IV	XXX (XX.X%)	XXX (XX.X%)		
Degree of limb swelling				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mild	XXX (XX.X%)	XXX (XX.X%)		
Moderate	XXX (XX.X%)	XXX (XX.X%)		
Severe	XXX (XX.X%)	XXX (XX.X%)		

Table 19 Statistical analysis results of subjects' preoperative fractures

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

	8 .			
Indicator	Study group	Control group	Statistics	P value
Fracture site - Lower limbs				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Left	XXX (XX.X%)	XXX (XX.X%)		
Right	XXX (XX.X%)	XXX (XX.X%)		
Type of trochanteric fracture				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Simple pertrochanteric fracture (31-A1)	XXX (XX.X%)	XXX (XX.X%)		
Comminuted pertrochanteric fracture (31-A2)	XXX (XX.X%)	XXX (XX.X%)		
Intertrochanteric fracture (31- A3)	XXX (XX.X%)	XXX (XX.X%)		
Type of fracture				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Open	XXX (XX.X%)	XXX (XX.X%)		
Closed	XXX (XX.X%)	XXX (XX.X%)		
Reason for fracture				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
High energy damage (such as, MVA)	XXX (XX.X%)	XXX (XX.X%)		
Low energy damage (such as, a fall in a standing position)	XXX (XX.X%)	XXX (XX.X%)		
Others	XXX (XX.X%)	XXX (XX.X%)		
Whether there are other fractures or no	ot			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Table 20 Statistical analysis results of subjects' x-ray examination before surgery

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Intramedullary nails - Product No.				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
Head elements - Product No.				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
Whether to implant distal locking sci	ews			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Distal locking screws - Product No.				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
Whether to implant proximal locking	g screws			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Proximal locking screws - Product N	0.			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
Whether to implant intermediate lock	king screws			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Table 21Statistical analysis results of subjects' use of investigational
devices

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

51/129

Indicator	Study group	Control group	Statistics	P value
Intermediate locking screws - Produc		<u> </u>	<u> </u>	1 Vulue
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
l				
End caps - Product No.				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		
XXXXX	XXX (XX.X%)	XXX (XX.X%)		

Table 21Statistical analysis results of subjects' use of investigational
devices (continued)

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Any other internal or external fixatio	n is used at the same t	ime		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site of application				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Femur	XXX (XX.X%)	XXX (XX.X%)		
Tibia and fibula	XXX (XX.X%)	XXX (XX.X%)		
Ulna and radius	XXX (XX.X%)	XXX (XX.X%)		
Humerus	XXX (XX.X%)	XXX (XX.X%)		
Others	XXX (XX.X%)	XXX (XX.X%)		

Table 22 Statistical analysis results of subjects' use of other devices

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Surgery time (hour)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Intraoperative blood loss volume (ml	L)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Intraoperative blood transfusion volu	ıme (mL)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Specific components of intraoperativ	e blood transfusion			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Concentrated red blood cell	XXX (XX.X%)	XXX (XX.X%)		
Whole blood	XXX (XX.X%)	XXX (XX.X%)		
Platelet	XXX (XX.X%)	XXX (XX.X%)		
Fresh frozen plasma (FFR)	XXX (XX.X%)	XXX (XX.X%)		
Others	XXX (XX.X%)	XXX (XX.X%)		

Table 23 Statistical analysis results of subjects' surgical details

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

3. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
Closed fracture				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
C 0	XXX (XX.X%)	XXX (XX.X%)		
CI	XXX (XX.X%)	XXX (XX.X%)		
CII	XXX (XX.X%)	XXX (XX.X%)		
C III	XXX (XX.X%)	XXX (XX.X%)		
Open fracture				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
0	Ι	XXX (XX.X%)	XXX (XX.X%)	
O II	XXX (XX.X%)	XXX (XX.X%)		
O III	XXX (XX.X%)	XXX (XX.X%)		
O IV	XXX (XX.X%)	XXX (XX.X%)		
Degree of limb swelling				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mild	XXX (XX.X%)	XXX (XX.X%)		
Moderate	XXX (XX.X%)	XXX (XX.X%)		
Severe	XXX (XX.X%)	XXX (XX.X%)		
Whether there is vascular injury?				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Whether there is nerve injury?				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Volume of drainage 24 hours after st	urgery (mL)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Method for reduction of fracture				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Closed reduction	XXX (XX.X%)	XXX (XX.X%)		
Open reduction	XXX (XX.X%)	XXX (XX.X%)		

Table 24 Statistical analysis results of subjects' intraoperative fractures

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

3. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
Reaming				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Not reamed	XXX (XX.X%)	XXX (XX.X%)		
Reamed	XXX (XX.X%)	XXX (XX.X%)		
Diameter after reaming (mm)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Incision closure				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Tension-free suture	XXX (XX.X%)	XXX (XX.X%)		
Tension suture	XXX (XX.X%)	XXX (XX.X%)		
Non-direct closure	XXX (XX.X%)	XXX (XX.X%)		
Whether there is device-related even	nt			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Table 24Statistical analysis results of subjects' intraoperative fractures
(continued)

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

3. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
Difficulty level of determining the na	ail application position	1		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Good	XXX (XX.X%)	XXX (XX.X%)		
Average	XXX (XX.X%)	XXX (XX.X%)		
Poor	XXX (XX.X%)	XXX (XX.X%)		
Difficulty level of inserting an intran	nedullary nail			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Good	XXX (XX.X%)	XXX (XX.X%)		
Average	XXX (XX.X%)	XXX (XX.X%)		
Poor	XXX (XX.X%)	XXX (XX.X%)		
Difficulty level of proximal locking				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Good	XXX (XX.X%)	XXX (XX.X%)		
Average	XXX (XX.X%)	XXX (XX.X%)		
Poor	XXX (XX.X%)	XXX (XX.X%)		
Difficulty level of distal locking				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Good	XXX (XX.X%)	XXX (XX.X%)		
Average	XXX (XX.X%)	XXX (XX.X%)		
Poor	XXX (XX.X%)	XXX (XX.X%)		
Difficulty level of placing end caps				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Good	XXX (XX.X%)	XXX (XX.X%)		
Average	XXX (XX.X%)	XXX (XX.X%)		
Poor	XXX (XX.X%)	XXX (XX.X%)		
Whether the placement of intramedu	llary nails has an imp	act on restoration		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No impact	XXX (XX.X%)	XXX (XX.X%)		
Better than before	XXX (XX.X%)	XXX (XX.X%)		
Worse than before	XXX (XX.X%)	XXX (XX.X%)		
Instrument and its quantity				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Good	XXX (XX.X%)	XXX (XX.X%)		
Average	XXX (XX.X%)	XXX (XX.X%)		
Poor	XXX (XX.X%)	XXX (XX.X%)		
Tools in the toolbox				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Good	XXX (XX.X%)	XXX (XX.X%)		
Average	XXX (XX.X%)	XXX (XX.X%)		
Poor	XXX (XX.X%)	XXX (XX.X%)		

Table 25Statistical analysis results of subjects'evaluation on productoperability and tools during the surgery

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Whether there are adverse events or c	complications in the s	ubjects during the su	rgery	
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Table 26 Statistical analysis results of subjects' intraoperative AEs

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 27Statistical analysis results of subjects' intraoperative medication
records

Indicator	Study group	Control group	Statistics	P value
Whether new drugs are added to the or medication is changed	concomitant medicat	ion or whether the or	iginal concom	itant
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 28Statistical analysis results of subjects' intraoperative
combination therapy

Indicator	Study group	Control group	Statistics	P value
Whether new types of combination the	herapy are added			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 29 (FAS) Primary endpoint - statistical analysis results of fracture
union rate of subjects at each site 24 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
Site 01 Beijing Jishuitan Hospital - S				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	· · · ·		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 02 Peking University Third Hosp			after surgery	
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)			
No	XXX (XX.X%)	XXX (XX.X%)		
Site 03 Chinese PLA General Hospita	al - Successful fractur		er surgery	
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 04 The Second Affiliated Hospit union 24 weeks after surgery	al of Zhejiang Univer	sity School of Medic	ine - Success	ful fracture
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 05 Shanghai General Hospital - S	· · · · ·	· · · · · · · · · · · · · · · · · · ·	urgerv	
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	· · · ·		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 05 Nanfang Hospital of Southern			union 24 wee	ks after
surgery	-			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 07 The First Affiliated Hospital	of Nantong University	y - Successful fractur	e union 24 we	eks after
surgery				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	· · · · · · · · · · · · · · · · · · ·		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 08 West China Hospital, Sichuar				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 09 The First Affiliated Hospital out of the state of	of Guangzhou Univer	sity of Chinese Medi	cine - Succes	sful fracture
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 10 University of Hong Kong - Sl surgery	henzhen Hospital - Su	accessful fracture uni	on 24 weeks a	lfter
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
		(

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases -- --- -- --- -- -

Table 29 (FAS) Primary endpoint - statistical analysis results of fractureunion rate of subjects at each site 24 weeks after surgery (continued)

Indicator	Study group	Control group	Statistics	P value
#1 merged site- Successful fracture u	nion 24 weeks after s	urgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. #1: hospital XXX, hospital XXX and hospital XXX merged;

2. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

			-	
Indicator	Study group	Control group	Statistics	P value
Successful fracture union 24 weeks at	ter surgery ^{#1}			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Difference in success rate (study group - c	ontrol group) and 95% CI	XX.X% [XX.X	%; XX.X%]	
P value in non-inferiori	e 1/	X.XXXX		
Difference in success rate (study group - c	ontrol group) and 95% CI	XX.X% [XX.X	%; XX.X%]	
P value in non-inferiori	ty test #4	X.XXXX		
Successful fracture union 24 weeks at	ter surgery ^{#2}			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)		
Yes	XXX (XX.X%)	XXX		
		(XX.X%)		
No	XXX (XX.X%)	XXX		
		(XX.X%)		
Difference in success rate (study group - c	ontrol group) and 95% CI	XX.X% [XX.X	%; XX.X%]	
P value in non-inferiori	ty test #3	X.XXXX		
Difference in success rate (study group - c	• •	XX.X% [XX.X	%; XX.X%]	
P value in non-inferiori	ty test #4	X.XXXX		

Table 30 (FAS) Primary endpoint - Statistical analysis results of subjects'fracture union rate 24 weeks after surgery

Notes: 1. #3 is analyzed by CMH chi-square test with adjusted sites, estimate the difference in success rate and non-inferiority test the P value;

#4 is analyzed by Continuous correction Newcombe-Wilson for non-adjusted central, estimate the difference in success rate and non-inferiority test the P value;

2. #1: The primary efficacy indicators of the subjects lost to follow-up during the trial were not processed;

#2: The primary efficacy indicators of the subjects lost to follow-up during the trial were carried forward by LOCF;

3. If the lower limit of 95% CI of the difference in the rates of the study group and the control group is greater than the non-inferiority margin of -10%, then the investigational product is considered non-inferior to the control product, i.e., the non-inferiority conclusion is established in this trial.

Indicator	Study group	Control group	Statistics	P value
Site 01 Beijing Jishuitan Hospital - Su	accessful fracture unio	on 24 weeks after su	rgery	
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 02 Peking University Third Hosp	ital - Successful fract	ure union 24 weeks	after surgery	
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 03 Chinese PLA General Hospita	l - Successful fractur	e union 24 weeks aft	ter surgery	
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 04 The Second Affiliated Hospita	· · · · · ·	· · · · ·	cine - Success	ful fracture
union 24 weeks after surgery	5 0	2		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 05 Shanghai General Hospital - S	uccessful fracture un	· · · · · · · · · · · · · · · · · · ·	urgery	
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 05 Nanfang Hospital of Southern	Medical University -	Successful fracture	union 24 wee	ks after
surgery				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 07 The First Affiliated Hospital of	f Nantong University	- Successful fractur	re union 24 we	eeks after
surgery				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 08 West China Hospital, Sichuan	University - Success	ful fracture union 24	weeks after s	urgery
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 09 The First Affiliated Hospital o union 24 weeks after surgery	f Guangzhou Univers	sity of Chinese Med	icine - Succes	sful fracture
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Site 10 University of Hong Kong - Sh	· · · · · ·	· · · · ·	on 24 weeks a	ıfter
surgery	1 1			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
	· · · · · ·	· /		

XXX (XX.X%)

Table 31 (PPS) Primary endpoint - statistical analysis results of fractureunion rate of subjects at each site 24 weeks after surgery

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

No

Version No.: V1.0

XXX (XX.X%)

Table 31	(PPS) Primary endpoint - statistical analysis results of fracture
union rate	e of subjects at each site 24 weeks after surgery (continued)

Indicator	Study group	Control group	Statistics	P value
#1 merged site- Successful fracture u	nion 24 weeks after s	urgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. #1: hospital XXX, hospital XXX and hospital XXX merged;

2. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 32 (PPS) Primary endpoint - Statistical analysis results of subjects'fracture union rate 24 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
Successful fracture union 24 weeks a	fter surgery			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Difference in success rate (study group - c	control group) and 95% (CI XX.X% [XX.X	[%; XX.X%]	
P value in non-inferiori	ity test #1	X.XXXX		
Difference in success rate (study group - c	control group) and 95% (CI XX.X% [XX.X	X%; XX.X%]	
P value in non-inferior	ity test #2	X.XXXX		

Notes: 1. #1 is analyzed by CMH chi-square test with adjusted sites, estimate the difference in success rate and non-inferiority test the P value;

#2 is analyzed by Continuous correction Newcombe-Wilson for non-adjusted central, estimate the difference in success rate and non-inferiority test the P value;

2. If the lower limit of 95% CI of the difference in the rates of the study group and the control group is greater than the non-inferiority margin of -10%, then the investigational product is considered non-inferior to the control product, i.e., the non-inferiority conclusion is established in this trial.

Table 33 (ATS) Primary endpoint - Statistical analysis results of subjects'fracture union rate 24 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
Successful fracture union 24 weeks a	ifter surgery			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Difference in success rate (study group - P value in non-inferior		CI XX.X% [XX.X X.XXXX	X%; XX.X%]	
Difference in success rate (study group - P value in non-inferior		CI XX.X% [XX.X X.XXXX	X%; XX.X%]	

Notes: 1. #1 is analyzed by CMH chi-square test with adjusted sites, estimate the difference in success rate and non-inferiority test the P value;

#2 is analyzed by Continuous correction Newcombe-Wilson for non-adjusted central, estimate the difference in success rate and non-inferiority test the P value;

2. ATS = PPS + The number of subjects with cross enrollment but without other serious violations of the study protocol.

3. If the lower limit of 95% CI of the difference in the rates of the study group and the control group is greater than the non-inferiority margin of -10%, then the investigational product is considered non-inferior to the control product, i.e., the non-inferiority conclusion is established in this trial.

Indicator	Study group	Control group	Statistics	P value
Total number of AEs				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Table 34 (FAS) Secondary endpoint - Statistical analysis results of adverseevents of subjects

Notes: 1. The total number of AEs refers to the number of subjects suffering from AEs, and the AEs occur in the subject at least one time, which is considered as "Yes".

2. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

3. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

68/129

Table 35 (FAS) Secondary endpoint - Statistical analysis results of
subjects' revision rate 24 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
Whether revision is required 24 week	s after surgery			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Whether re-operation is required 24 w	veeks after surgery			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 37 (FAS) Secondary endpoint - Statistical analysis results of
subjects' Harris hip score 12 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
Total Harris hip score				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

3. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

71/129

Table 38 (FAS) Secondary endpoint - Statistical analysis results of
subjects' Harris hip score 24 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
Total Harris hip score				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
SF-12 score (body functions)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
(1 mbs) Mean \pm SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX XX.XX	XX.XX XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum				
-	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (body		• •	V VVVV	V VVVV
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX ,XX.XX)		
The difference and 95% confidence interval	XX.XX(XX.XX ,XX.X	X)		
SF-12 score (physical condit	tions)			
Number of subjects	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
(N miss)			Λ.ΛΛΛΛ	Λ.ΛΛΛΛ
Mean \pm SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (phys		e to before surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
	(XX.XX ,XX.XX)	(XX.XX,XX.XX)		
	.XX(XX.XX ,XX.XX)			
interval				
SF-12 score (body pain)				
Number of subjects	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
(N miss)			Λ.ΛΛΛΛ	Λ.ΛΛΛΛ
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
N 6 ² · · · ·	3737 3737 3737 3737 3737	X/X/ X/X/ X/X/ X/X/		

Table 39 (FAS) Secondary endpoint - Statistical analysis results of
subjects' SF-12v2 questionnaire 12 weeks after surgery

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

XX.XX ;XX.XX

Minimum; maximum

XX.XX ;XX.XX

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

3. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Table 39 (FAS) Secondary endpoint - Statistical analysis results ofsubjects' SF-12v2 questionnaire 12 weeks after surgery (continued 1)

Indicator	Study group	Control group	Statistics	P value
SF-12 score (general health)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (gener	al health) relative to be	fore surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
	XX.XX,XX.XX)	(XX.XX,XX.XX)		
interval				
The difference and XX.	XX(XX.XX,XX.XX)			
95% confidence				
interval				
SF-12 score (vitality)				
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)				
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (vitali	ty) relative to before su	rgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence (interval	XX.XX ,XX.XX)	(XX.XX ,XX.XX)		
The difference and XX.2 95% confidence interval	XX(XX.XX ,XX.XX)			

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

SF-12 score (social functions)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (socia	l functions) relative to b	before surgery		
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)				
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence	(XX.XX, XX.XX)	(XX.XX,XX.XX)		
interval				
	XX(XX.XX ,XX.XX)			
95% confidence interval				
mut vai				

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
SF-12 score (emotional cond	litions)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (emo	tional conditions) relativ	ve to before surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX ,XX.XX)		
The difference and XX 95% confidence interval	.XX(XX.XX ,XX.XX)			
SF-12 score (mental health)				
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)				
Mean \pm SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (men	· · · · · · · · · · · · · · · · · · ·			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX ,XX.XX)		
95% confidence interval	.XX(XX.XX ,XX.XX)			
SF-12 score (total physical h	/	3/3/3/ / 3/3/3/	1 7 1717 7 7 77	X7 X7X7X7
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Medical Research & Biometrics C	· · · · · · · · · · · · · · · · · · ·	Version No.:	V1.0	76/1

Table 39 (FAS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 questionnaire 12 weeks after surgery (continued 2)

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

Change in SF-12 score (total physical health score) relative to before surgery				
Number of subjects (1 miss)	N XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX,XX.XX)	(XX.XX ,XX.XX)		
The difference and 5% confidence interval	XX.XX(XX.XX ,XX.XX)			

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

quantitative indicators.

Indicator	Study group	Control group	Statistics	P value
SF-12 score (total mental health	score)			
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)				
Mean \pm SD	XX.XX ±XX.XX	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (total men	ntal health score) relat	tive to before surgery		
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)				
Mean \pm SD	XX.XX ±XX.XX	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence (X	X.XX ,XX.XX)	(XX.XX, XX.XX)		
interval				
The difference and XX.XX	X(XX.XX,XX.XX)			
95% confidence				
interval				

Table 39 (FAS) Secondary endpoint - Statistical analysis results ofsubjects' SF-12v2 questionnaire 12 weeks after surgery (continued 3)

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Table 40 (FAS) Secondary endpoint - Statistical analysis results of
subjects' SF-12v2 questionnaire 24 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
SF-12 score (body functions)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (body		fore surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX,XX.XX)	(XX.XX ,XX.XX)		
	.XX(XX.XX ,XX.XX)			
interval				
SF-12 score (physical condition	ons)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (physic	cal conditions) relative t	o before surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX,XX.XX)	(XX.XX,XX.XX)		
The difference and XX 95% confidence interval	.XX(XX.XX ,XX.XX)			
SF-12 score (body pain)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	XX.XX ±XX.XX	$XX.XX \pm XX.XX$		
Median	XX.XX XX.XX	XX.XX XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

Change in SF-12 score (bo	ody pain) relative to before s	surgery		
Number of subjects (1 miss)	N XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX,XX.XX)		
The difference and 95% confidence interval	XX.XX(XX.XX ,XX.XX)			

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Table 40 (FAS) Secondary endpoint - Statistical analysis results ofsubjects' SF-12v2 questionnaire 24 weeks after surgery (continued 1)

Indicator	Study group	Control group	Statistics	P value
SF-12 score (general health)				
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)				
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (gene	eral health) relative to befo	ore surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX,XX.XX)		
The difference and X 95% confidence interval	X.XX(XX.XX ,XX.XX)			
SF-12 score (vitality)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Medical Research & Biometrics Center for Cardiovascular Diseas	Center, National	Version No.: V1.0		80/12

Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (vital			V VVVV	V VVVV
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	XX.XX ±XX.XX	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX ,XX.XX)		
The difference and XI 95% confidence interval	X.XX(XX.XX ,XX.XX)			
SF-12 score (social functions	5)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean ± SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX;XX.XX		
Change in SF-12 score (socia	al functions) relative to be	fore surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
$Mean \pm SD$	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX,XX.XX)	(XX.XX ,XX.XX)		
The difference and X 95% confidence	X.XX(XX.XX ,XX.XX)			

- Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.
 - 2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

3. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

81/129

Indicator	Study group	Control group	Statistics	P value
SF-12 score (emotional conditions))			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (emotional	conditions) relative	to before surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence (XX interval	.XX ,XX.XX)	(XX.XX,XX.XX)		
The difference and XX.XX(95% confidence interval	XX.XX ,XX.XX)			
SF-12 score (mental health)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	XX.XX ±XX.XX	· · · · ·	11.11.11.11	11.1111111
Median	XX.XX	XX.XX		
z Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (mental hea		-		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	XX.XX ±XX.XX	· · · · ·	11.11.11.11	11.11.11.11
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX			
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
	.XX,XX.XX)	(XX.XX,XX.XX)		
interval				
	XX.XX ,XX.XX)			
95% confidence				
interval SF-12 score (total physical health s	acore)			
· · ·	·	VVV (VVV)	y yvvv	X.XXXX
Number of subjects (N miss) Mean ± SD	XXX (XXX) XX.XX ±XX.XX	XXX (XXX) XX.XX ±XX.XX	X.XXXX	Λ.ΛΛλ
Median	$\Lambda\Lambda.\Lambda\Lambda \pm\Lambda\Lambda.\Lambda\Lambda$ XX.XX	$XX.XX \pm XX.XX$		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (total physic			V VVVVV	¥7 ¥7¥7¥7¥
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	XX.XX ±XX.XX			
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		

Table 40 (FAS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 questionnaire 24 weeks after surgery (continued 2)

82/129

Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX	
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX,XX.XX)	
The difference and 95% confidence interval	XX.XX(XX.XX ,XX.XX)		

- Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.
 - 2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Table 40 (FAS) Secondary endpoint - Statistical analysis results ofsubjects' SF-12v2 questionnaire 24 weeks after surgery (continued 3)

Indicator	Study group	Control group	Statistics	P value
SF-12 score (total mental health sco	ore)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (total menta	al health score) relat	ive to before surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence (XX	.XX,XX.XX)	(XX.XX, XX.XX)		
interval				
The difference and XX.XX(XX.XX, XX.XX)			
95% confidence				
interval				

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator		Control group	Statistics	P value
Activity level				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Walk easily	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to walk	XXX (XX.X%)	XXX (XX.X%)		
Self-care				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Easy to wash or dress independently	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to wash or dress independently	XXX (XX.X%)	XXX (XX.X%)		
Daily activities (such as work, study, house	work, family or ent	ertainment)		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Easy to perform daily activities	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to perform daily activities	XXX (XX.X%)	XXX (XX.X%)		
Pain/discomfort				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Mild pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Moderate pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Severe pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Very severe pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Anxiety/depression		, , ,		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Mild anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Moderate anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Severe anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Very severe anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		

Table 41 (FAS) Secondary endpoint - Statistical analysis results of
subjects' EQ-5D questionnaire 12 weeks after surgery

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the

intergroup comparison of qualitative indicators;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Table 41 (FAS) Secondary endpoint - Statistical analysis results of
subjects' EQ-5D questionnaire 12 weeks after surgery(continue)

Indicator	Study	/ group	Control gro	oup	Statist	ics P value
$Mean \pm SD$	$XX.XX \pm XX.XX$	XX.XX	K±XX.XX			
Median	XX.XX	Х	X.XX			
Q1; Q3	XX.XX ;XX.XX	XX.X	X ;XX.XX			
Minimum; maximum	XX.XX ;XX.XX	XX.X	X ;XX.XX			
Change in health index relativ	ve to before surgery					
Number of subjects (N miss)	XXX (XXX)	XXX	(XXX)	X.XX	XX	X.XXXX
$Mean \pm SD$	$XX.XX \pm XX.XX$	XX.XX	K±XX.XX			
Median	XX.XX	X	X.XX			
Q1; Q3	XX.XX ;XX.XX	XX.X	X ;XX.XX			
Minimum; maximum	XX.XX ;XX.XX	XX.X	X ;XX.XX			
95% confidence	(XX.XX, XX.XX)	(XX.XX	(XX.XX, X			
interval						
The difference and XX 95% confidence interval	X.XX(XX.XX ,XX.XX))				

- Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.
 - 2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

3. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Activity level				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Walk easily	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to walk	XXX (XX.X%)	XXX (XX.X%)		
Self-care				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Easy to wash or dress independently	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to wash or dress independently	XXX (XX.X%)	XXX (XX.X%)		
Daily activities (such as work, study, house	work, family or ent	ertainment)		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Easy to perform daily activities	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to perform daily activities	XXX (XX.X%)	XXX (XX.X%)		
Pain/discomfort				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Mild pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Moderate pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Severe pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Very severe pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Anxiety/depression	. ,	. ,		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Mild anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Moderate anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Severe anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Very severe anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		

Table 42 (FAS) Secondary endpoint - Statistical analysis results of
subjects' EQ-5D questionnaire 24 weeks after surgery

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the

intergroup comparison of qualitative indicators;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Table 42 (FAS) Secondary endpoint - Statistical analysis results of
subjects' EQ-5D questionnaire 24 weeks after surgery(continue)

Indicator	Study	group	Control grou	ıp Statis	stics	P value
Health index						
Number of subjects (N mis	ss) XXX (XXX)	XXX (XXX	X) X.XX	XX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	XX.XX	$X \pm XX.XX$			
Median	XX.XX	X	X.XX			
Q1; Q3	XX.XX ;XX.XX	XX.XX	X ;XX.XX			
Minimum; maximum	XX.XX ;XX.XX	XX.XX	X ;XX.XX			
Change in health index relativ	e to before surgery					
Number of subjects (N miss)	XXX (XXX)	XXX	(XXX)	X.XXXX	X.X	XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	XX.XX	$X \pm XX.XX$			
Median	XX.XX	X	X.XX			
Q1; Q3	XX.XX ;XX.XX	XX.XX	X ;XX.XX			
Minimum; maximum	XX.XX ;XX.XX	XX.XX	X ;XX.XX			
95% confidence	(XX.XX,XX.XX)	(XX.XX	X,XX.XX)			
interval						
The difference and XX	.XX(XX.XX,XX.XX)					
95% confidence						
interval						

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

3. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

4. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Table 43 (FAS) Secondary endpoint - Statistical analysis results ofsubjects' incidence rate of complications requiring re-operation or revision

Indicator	Study group	Control group	Statistics	P value
Complications requiring re-operation	on or revision			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 44 (PPS) Secondary endpoint - Statistical analysis results of
subjects' AE

Indicator	Study group	Control group	Statistics	P value
Total No.				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. Total No.: the number of subjects who occurred AE, if at least once, will be determined as 'Y'

2. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 45 (PPS) Secondary endpoint - Statistical analysis results of
subjects' revision rate 24 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
Revision 24 weeks after surgery				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 46 (PPS) Secondary endpoint - Statistical analysis results of
subjects' re-operation rate 24 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
Re-operation 24 weeks after surgery				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Total Harris hip score				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Table 48 (PPS) Secondary endpoint - Statistical analysis results of
subjects' Harris hip score 24 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
Total Harris hip score				
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)				
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
SF-12 score (body function	ns)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (bo	dy functions) relative to b	before surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX,XX.XX)	(XX.XX ,XX.XX)		
The difference and 95% confidence interval	XX.XX(XX.XX ,XX.X	X)		
SF-12 score (physical cond	litions)			
Number of subjects	,	VVV (VVV)	X.XXXX	v vvvv
(N miss)	XXX (XXX)	XXX (XXX)	Λ.ΛΛΛΛ	X.XXXX
Mean \pm SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (ph	-			37 37373737
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence	(XX.XX,XX.XX)	(XX.XX,XX.XX)		
interval				
	X.XX(XX.XX,XX.XX)			
95% confidence interval				
SF-12 score (body pain)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
$Mean \pm SD$	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX ±XX.XX XX.XX	XX.XX ±XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX XX.XX ;XX.XX		

 Table 49 (FAS) Secondary endpoint - Statistical analysis results of
 subjects' SF-12v2 questionnaire 12 weeks after surgery

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

3. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Table 49 (PPS) Secondary endpoint - Statistical analysis results ofsubjects' SF-12v2 questionnaire 12 weeks after surgery (continued 1)

Indicator	Study group	Control group	Statistics	P value
SF-12 score (general health))			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (gen	eral health) relative to be	fore surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean ± SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence	(XX.XX,XX.XX)	(XX.XX,XX.XX)		
interval				
The difference and XX	X.XX(XX.XX ,XX.XX)			
95% confidence				
interval				
SF-12 score (vitality)				
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)				
Mean \pm SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (vita	• /	rgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX ,XX.XX)		
The difference and XX 95% confidence interval	X.XX(XX.XX ,XX.XX)			

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

SF-12 score (social functions)				
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)				
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (social	functions) relative to l	before surgery		
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)				
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence (X	(X.XX, XX.XX)	(XX.XX,XX.XX)		
interval				
The difference and XX.X	X(XX.XX ,XX.XX)			
95% confidence				
interval				

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
SF-12 score (emotional cond	litions)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (emo	tional conditions) relativ	ve to before surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX ,XX.XX)		
The difference and XX 95% confidence interval	.XX(XX.XX ,XX.XX)			
SF-12 score (mental health)				
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)			Λ.ΛΛΛΛ	Λ.ΛΛΛΛ
Mean \pm SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (men				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX,XX.XX)	(XX.XX ,XX.XX)		
95% confidence interval	.XX(XX.XX ,XX.XX)			
SF-12 score (total physical h	· · · · · · · · · · · · · · · · · · ·			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Medical Research & Biometrics (Version No.:	V1.0	98/1

Table 49 (PPS) Secondary endpoint - Statistical analysis results of subjects' SF-12v2 questionnaire 12 weeks after surgery (continued 2)

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

Change in SF-12 score	(total physical health score) re	elative to before surge	ry	
Number of subjects miss)	(N XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximu	m XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX ,XX.XX)		
The difference and 95% confidence interval	XX.XX(XX.XX ,XX.XX)			

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

3. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

99/129

Indicator	Study group	Control group	Statistics	P value
SF-12 score (total mental health	score)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (total me	ental health score) relat	ive to before surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence (2 interval	(X.XX, XX.XX)	(XX.XX,XX.XX)		
	X(XX.XX ,XX.XX)			

Table 49 (PPS) Secondary endpoint - Statistical analysis results ofsubjects' SF-12v2 questionnaire 12 weeks after surgery (continued 3)

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Table 50 (PPS) Secondary endpoint - Statistical analysis results of
subjects' SF-12v2 questionnaire 24 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
SF-12 score (body functions))			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX\pm\!XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (body	y functions) relative to be	fore surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX,XX.XX)		
	X.XX(XX.XX ,XX.XX)			
interval				
SF-12 score (physical condit	ions)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX\pm\!XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (phys	sical conditions) relative t	o before surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX\pm\!XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX ,XX.XX)		
95% confidence interval	X.XX(XX.XX ,XX.XX)			
SF-12 score (body pain)	VVV (VVV)	VVV (VVV)	V VVVV	V VVVV
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Medical Research & Biometrics (Version No.: V1	.0	101/129

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

Change in SF-12 score (bo	dy pain) relative to before s	surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX ,XX.XX)		
The difference and 2 95% confidence interval	XX.XX(XX.XX ,XX.XX)			

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

3. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

 Table 50 (PPS) Secondary endpoint - Statistical analysis results of
 subjects' SF-12v2 questionnaire 24 weeks after surgery (continued 1)

Indicator	Study group	Control group	Statistics	P value
SF-12 score (general health)				
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)				
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (gene	eral health) relative to befor	ore surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX,XX.XX)		
The difference and X2 95% confidence interval	X.XX(XX.XX ,XX.XX)			
SF-12 score (vitality)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Medical Research & Biometrics C Center for Cardiovascular Diseas		Version No.: V1.0		102/12

Center for Cardiovascular Diseases

Minimum; maximum Change in SF-12 score (vitalit	XX.XX ;XX.XX tv) relative to before surg	XX.XX ;XX.XX		
Number of subjects (N	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
miss)		ΛΛΛ (ΛΛΛ)	Λ.ΛΛΛ	Λ.ΛΛΛΛ
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX ,XX.XX)		
The difference and XX 95% confidence interval	X.XX(XX.XX ,XX.XX)			
SF-12 score (social functions)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (social	l functions) relative to be	fore surgery		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX,XX.XX)		
The difference and XX 95% confidence	XX(XX.XX ,XX.XX)			
interval				

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

3. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

103/129

Indicator	Study group	Control group	Statistics	P value
SF-12 score (emotional conditions)				
Number of subjects (N miss)	, XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	XX.XX ±XX.XX		_	_
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX			
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (emotional				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean ± SD	XX.XX ±XX.XX	XX.XX ±XX.XX		
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
	.XX ,XX.XX)	(XX.XX,XX.XX)		
interval	(1/1/ 1/1/ 1/1/ 1/1/			
The difference and XX.XX(95% confidence	(XX.XX ,XX.XX)			
interval				
SF-12 score (mental health)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	XX.XX ±XX.XX	· · · ·	A.2020	<i><i><i><i><i><i><i></i></i></i></i></i></i></i>
Median	XX.XX	XX.XX		
z Q1;Q3	XX.XX ;XX.XX			
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (mental hea				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	XX.XX ±XX.XX		1.1.1.1.1.1.1	1.1.1.1.1.1.1
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX			
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX		
	.XX ,XX.XX)	(XX.XX ,XX.XX)		
interval	(3/3/ 3/3/ 3/3/ 3/3/			
	(XX.XX ,XX.XX)			
95% confidence interval				
SF-12 score (total physical health s	score)			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$. ,	Λ.ΛΛΛΛ	Λ.ΛΛΛΛ
Median	XX.XX	XX.XX		
Q1;Q3	XX.XX ;XX.XX	XX.XX ;XX.XX		
Q1;Q3 Minimum; maximum				
,	XX.XX ;XX.XX	XX.XX ;XX.XX		
Change in SF-12 score (total physical Number of subjects (Number)	· · · · ·		v vvvv	V VVVV
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX

Table 50 (PPS) Secondary endpoint - Statistical analysis results ofsubjects' SF-12v2 questionnaire 24 weeks after surgery (continued 2)

Q1;Q3 XX.XX ;XX.XX XX ;XX.XX Medical Research & Biometrics Center, National Version No.: V1.0 Center for Cardiovascular Diseases

 $XX.XX \pm XX.XX$

XX.XX

 $XX.XX\pm\!XX.XX$

XX.XX

 $Mean \pm SD$

Median

104/129

Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX	
95% confidence interval	(XX.XX ,XX.XX)	(XX.XX,XX.XX)	
The difference and 95% confidence interval	XX.XX(XX.XX ,XX.XX)		

- Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.
 - 2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Table 50 (PPS) Secondary endpoint - Statistical analysis results ofsubjects' SF-12v2 questionnaire 24 weeks after surgery (continued 3)

Indicator	Study group	Control group	Statistics	P value		
SF-12 score (total mental health score)						
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX		
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$				
Median	XX.XX	XX.XX				
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX				
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX				
Change in SF-12 score (total mental health score) relative to before surgery						
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX		
Mean \pm SD	$XX.XX \pm XX.XX$	$XX.XX \pm XX.XX$				
Median	XX.XX	XX.XX				
Q1; Q3	XX.XX ;XX.XX	XX.XX ;XX.XX				
Minimum; maximum	XX.XX ;XX.XX	XX.XX ;XX.XX				
95% confidence (XX	.XX,XX.XX)	(XX.XX, XX.XX)				
interval						
The difference and XX.XX(XX.XX, XX.XX)					
95% confidence						
interval						

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

Indicator	Study group	Control group	Statistics	P value
Activity level				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Walk easily	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to walk	XXX (XX.X%)	XXX (XX.X%)		
Self-care				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Easy to wash or dress independently	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to wash or dress independently	XXX (XX.X%)	XXX (XX.X%)		
Daily activities (such as work, study, house	work, family or ent	ertainment)		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Easy to perform daily activities	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to perform daily activities	XXX (XX.X%)	XXX (XX.X%)		
Pain/discomfort				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Mild pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Moderate pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Severe pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Very severe pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Anxiety/depression				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Mild anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Moderate anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Severe anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Very severe anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		

Table 51 (PPS) Secondary endpoint - Statistical analysis results of
subjects' EQ-5D questionnaire 12 weeks after surgery

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the

intergroup comparison of qualitative indicators;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Table 51 (PPS) Secondary endpoint - Statistical analysis results of
subjects' EQ-5D questionnaire 12 weeks after surgery(continue)

Indicator	Study	group	Control group	Statistics	P value
Health index					
Number of subjects ()	N miss) XXX (XXX)	XXX (XXX)	X.XXXX	X X.XXXX
$Mean \pm SD$	$XX.XX \pm XX.XX$	XX.XX	$X \pm XX.XX$		
Median	XX.XX	X	X.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX	X ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX	X ;XX.XX		
Change in health index re	elative to before surgery				
Number of subjects (N m	iiss) XXX (XXX)	XXX	X (XXX) X	XXXXX X	K.XXXX
$Mean \pm SD$	$XX.XX \pm XX.XX$	XX.XX	$X \pm XX.XX$		
Median	XX.XX	X	X.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX	X ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX	X ;XX.XX		
95% confidence	(XX.XX ,XX.XX)	(XX.XX	(XX.XX,		
interval					
The difference and	XX.XX(XX.XX ,XX.XX)				
95% confidence					
interval					

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

3. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Activity level			00 00 00 00 00 00 00 00 00 00 00	
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Walk easily	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in walking	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to walk	XXX (XX.X%)	XXX (XX.X%)		
Self-care				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Easy to wash or dress independently	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in washing or dressing independently	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to wash or dress independently	XXX (XX.X%)	XXX (XX.X%)		
Daily activities (such as work, study, house	work, family or ent	ertainment)		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Easy to perform daily activities	XXX (XX.X%)	XXX (XX.X%)		
Slightly difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Very difficult in performing daily activities	XXX (XX.X%)	XXX (XX.X%)		
Completely unable to perform daily activities	XXX (XX.X%)	XXX (XX.X%)		
Pain/discomfort				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Mild pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Moderate pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Severe pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Very severe pain/discomfort	XXX (XX.X%)	XXX (XX.X%)		
Anxiety/depression				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Mild anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Moderate anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Severe anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		
Very severe anxiety/depression	XXX (XX.X%)	XXX (XX.X%)		

Table 52 (PPS) Secondary endpoint - Statistical analysis results of
subjects' EQ-5D questionnaire 24 weeks after surgery

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the

intergroup comparison of qualitative indicators;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);;

Table 52 (PPS) Secondary endpoint - Statistical analysis results of
subjects' EQ-5D questionnaire 24 weeks after surgery(continue)

Indicator	Study	group	Control group	Statistics	P value
Health index					
Number of subjects (N i	miss) XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	XX.XX	±XX.XX		
Median	XX.XX	XX	K.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX	X ;XX.XX		
Minimum; maximum	XX.XX ;XX.XX	XX.XX	X ;XX.XX		
Change in health index rela	tive to before surgery				
Number of subjects (N miss	s) XXX (XXX)	XXX	(XXX) X	.XXXX X.	XXXX
Mean \pm SD	$XX.XX \pm XX.XX$	XX.XX	±XX.XX		
Median	XX.XX	XX	K.XX		
Q1; Q3	XX.XX ;XX.XX	XX.XX	X ;XX.XX;		
Minimum; maximum	XX.XX ;XX.XX	XX.XX	X ;XX.XX		
95% confidence	(XX.XX,XX.XX)	(XX.XX	,XX.XX)		
interval					
The difference and X	XX.XX(XX.XX ,XX.XX)				
95% confidence					
interval					

Notes: 1. Group t-test or Wilcoxon rank-sum test is used to analyze the intergroup comparison of quantitative indicators.

2. In quantitative indicators, Q1: 25th quantile, Q3: 75th percentile.

3. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 53 (PPS) Secondary endpoint - Statistical analysis results ofsubjects' incidence rate of complications requiring re-operation or revision

Indicator	Study group	Control group	Statistics	P value
Complications requiring re-operation	on or revision			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 54Statistical analysis results of subjects' AE evaluation 1 weeks
after surgery

Indicator	Study group	Control group	Statistics	P value
Whether there are adverse events or	complications in the	subjects after the last	t follow-up	
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 55	Statistical analysis results of subjects' medication records 1 week	Ĺ
	after surgery	

- -

Indicator	Study group	Control group	Statistics	P value	
Whether new drugs are added to the concomitant medication or whether the original concomitant					
medication is changed					
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX	
Yes	XXX (XX.X%)	XXX (XX.X%)			
No	XXX (XX.X%)	XXX (XX.X%)			

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

114/129

Statistical analysis results of subjects	combination therapy 1
week after surgery	

Indicator	Study group	Control group	Statistics	P value
Whether new types of combination the	rapy are added			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Wound healing - healing grade				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
А	XXX (XX.X%)	XXX (XX.X%)		
В	XXX (XX.X%)	XXX (XX.X%)		
С	XXX (XX.X%)	XXX (XX.X%)		
Wound healing - incision category				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Class I	XXX (XX.X%)	XXX (XX.X%)		
Class II	XXX (XX.X%)	XXX (XX.X%)		
Physical sign - Focal tenderness				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
NA	XXX (XX.X%)	XXX (XX.X%)		
Mild	XXX (XX.X%)	XXX (XX.X%)		
Severe	XXX (XX.X%)	XXX (XX.X%)		
Physical sign - Lengthwise percussion	pain			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
NA	XXX (XX.X%)	XXX (XX.X%)		
Mild	XXX (XX.X%)	XXX (XX.X%)		
Severe	XXX (XX.X%)	XXX (XX.X%)		
Physical sign - Abnormal activity				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Evaluate postoperative weight-bearing				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No weight-bearing	XXX (XX.X%)	XXX (XX.X%)		
Lower degree of weight-bearing (support with two crutches)	XXX (XX.X%)	XXX (XX.X%)		
Higher degree of weight-bearing (support with one crutch)	XXX (XX.X%)	XXX (XX.X%)		
Fully weight-bearing (support without crutch)	XXX (XX.X%)	XXX (XX.X%)		

Table 57 Statistical analysis results of subjects' fractures 1 week after surgery

stability of the fracture site

Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

		81		
Indicator	Study group	Control group	Statistics	P value
Reduction				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Stable	XXX (XX.X%)	XXX (XX.X%)		
Loss of reduction	XXX (XX.X%)	XXX (XX.X%)		
Is the re-operation required				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Implant				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Good	XXX (XX.X%)	XXX (XX.X%)		
Rupture of screw/bolt	XXX (XX.X%)	XXX (XX.X%)		
Rupture of intramedullary nail	XXX (XX.X%)	XXX (XX.X%)		
Displacement of screw/bolt	XXX (XX.X%)	XXX (XX.X%)		
Displacement of intramedullary nail	XXX (XX.X%)	XXX (XX.X%)		
Fracture line				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Clear	XXX (XX.X%)	XXX (XX.X%)		
Vague	XXX (XX.X%)	XXX (XX.X%)		
Disappeared	XXX (XX.X%)	XXX (XX.X%)		
Callus				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
NA	XXX (XX.X%)	XXX (XX.X%)		
Intermittent	XXX (XX.X%)	XXX (XX.X%)		
Continuous	XXX (XX.X%)	XXX (XX.X%)		

Table 58Statistical analysis results of subjects' x-ray examination at the
fracture site 1 week after surgery

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 59Statistical analysis results of subjects' AE evaluation 6 weeks
after surgery

Indicator	Study group	Control group	Statistics	P value
Whether there are adverse events or c	complications in the	subjects after the last	follow-up	
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
<u>No</u>	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 60Statistical analysis results of subjects' medication records 6weeks after surgery

Indicator	Study group	Control group	Statistics	P value		
Whether new drugs are added to the concomitant medication or whether the original concomitant medication is changed						
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX		
Yes	XXX (XX.X%)	XXX (XX.X%)				
No	XXX (XX.X%)	XXX (XX.X%)				

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Whether new types of combination th				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

	8 0			
Indicator	Study group	Control group	Statistics	P value
Wound healing - healing grade				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
А	XXX (XX.X%)	XXX (XX.X%)		
В	XXX (XX.X%)	XXX (XX.X%)		
С	XXX (XX.X%)	XXX (XX.X%)		
Wound healing - incision category				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Class I	XXX (XX.X%)	XXX (XX.X%)		
Class II	XXX (XX.X%)	XXX (XX.X%)		
Physical sign - Focal tenderness				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
NA	XXX (XX.X%)	XXX (XX.X%)		
Mild	XXX (XX.X%)	XXX (XX.X%)		
Severe	XXX (XX.X%)	XXX (XX.X%)		
Physical sign - Lengthwise percussion	pain			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
NA	XXX (XX.X%)	XXX (XX.X%)		
Mild	XXX (XX.X%)	XXX (XX.X%)		
Severe	XXX (XX.X%)	XXX (XX.X%)		
Physical sign - Abnormal activity				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Evaluate postoperative weight-bearing				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No weight-bearing	XXX (XX.X%)	XXX (XX.X%)		
Lower degree of weight-bearing (support with two crutches)	XXX (XX.X%)	XXX (XX.X%)		
Higher degree of weight-bearing (support with one crutch)	XXX (XX.X%)	XXX (XX.X%)		
Fully weight-bearing (support without crutch)	XXX (XX.X%)	XXX (XX.X%)		
After the investigational device is impla- stability of the fracture site	anted, whether exten	rnal fixation is requi	red to enhance	e the

Table 62Statistical analysis results of subjects' fractures 6 weeks after
surgery

stability of the fracture site Number of subjects (N miss)

Number of subjects	s (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes		XXX (XX.X%)	XXX (XX.X%)		
No		XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Reduction				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Stable	XXX (XX.X%)	XXX (XX.X%)		
Loss of reduction	XXX (XX.X%)	XXX (XX.X%)		
Is the re-operation required				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Implant				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Good	XXX (XX.X%)	XXX (XX.X%)		
Rupture of screw/bolt	XXX (XX.X%)	XXX (XX.X%)		
Rupture of intramedullary nail	XXX (XX.X%)	XXX (XX.X%)		
Displacement of screw/bolt	XXX (XX.X%)	XXX (XX.X%)		
Displacement of intramedullary nail	XXX (XX.X%)	XXX (XX.X%)		
Fracture line				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Clear	XXX (XX.X%)	XXX (XX.X%)	1.111111	71.71717171
Vague	XXX (XX.X%)	XXX (XX.X%)		
Disappeared	XXX (XX.X%)	XXX (XX.X%)		
Callus	11111 (111111) ()	/////(////////////////////////////////		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
NA	XXX (XX.X%)	XXX (XX.X%)		
Intermittent	XXX (XX.X%)	XXX (XX.X%)		
Continuous	XXX (XX.X%)	XXX (XX.X%)		
The frontal/lateral X-ray examination		· · · · · · · · · · · · · · · · · · ·	oss the fractur	e line
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Determine the fracture union condition	· · · · · ·	(
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No union	XXX (XX.X%)	XXX (XX.X%)		
Union	XXX (XX.X%)	XXX (XX.X%)		

Table 63Statistical analysis results of subjects' X-ray examination at the
fracture site 6 weeks after surgery

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Table 64Statistical analysis results of subjects' AE evaluation 12 weeks
after surgery

Indicator	Study group	Control group	Statistics	P value		
Whether there are adverse events or complications in the subjects after the last follow-up						
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX		
Yes	XXX (XX.X%)	XXX (XX.X%)				
No	XXX (XX.X%)	XXX (XX.X%)				

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

		01		
Indicator	Study group	Control group	Statistics	P value
Whether new drugs are added to the c medication is changed	concomitant medication	on or whether the or	iginal concom	itant
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 66Statistical analysis results of subjects' combination therapy 12weeks after surgery

Indicator	Study group	Control group	Statistics	P value		
Whether new types of combination therapy are added						
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX		
Yes	XXX (XX.X%)	XXX (XX.X%)				
No	XXX (XX.X%)	XXX (XX.X%)				

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value	
Wound healing - healing grade					
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX	
А	XXX (XX.X%)	XXX (XX.X%)			
В	XXX (XX.X%)	XXX (XX.X%)			
С	XXX (XX.X%)	XXX (XX.X%)			
Wound healing - incision category					
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX	
Class I	XXX (XX.X%)	XXX (XX.X%)			
Class II	XXX (XX.X%)	XXX (XX.X%)			
Physical sign - Focal tenderness					
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX	
NA	XXX (XX.X%)	XXX (XX.X%)			
Mild	XXX (XX.X%)	XXX (XX.X%)			
Severe	XXX (XX.X%)	XXX (XX.X%)			
Physical sign - Lengthwise percussion	pain				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX	
NA	XXX (XX.X%)	XXX (XX.X%)			
Mild	XXX (XX.X%)	XXX (XX.X%)			
Severe	XXX (XX.X%)	XXX (XX.X%)			
Physical sign - Abnormal activity					
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX	
Yes	XXX (XX.X%)	XXX (XX.X%)			
No	XXX (XX.X%)	XXX (XX.X%)			
Evaluate postoperative weight-bearing					
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX	
No weight-bearing	XXX (XX.X%)	XXX (XX.X%)			
Lower degree of weight-bearing (support with two crutches)	XXX (XX.X%)	XXX (XX.X%)			
Higher degree of weight-bearing (support with one crutch)	XXX (XX.X%)	XXX (XX.X%)			
Fully weight-bearing (support without crutch)	XXX (XX.X%)	XXX (XX.X%)			
After the investigational device is impl	anted, whether exte	rnal fixation is requi	red to enhance	e the	

Table 67Statistical analysis results of subjects' fractures 12 weeks after
surgery

After the investigational device is implanted, whether external fixation is required to enhance the stability of the fracture site

Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Reduction	i	U		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Stable	XXX (XX.X%)	XXX (XX.X%)		
Loss of reduction	XXX (XX.X%)	XXX (XX.X%)		
Is the re-operation required				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Implant				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Good	XXX (XX.X%)	XXX (XX.X%)		
Rupture of screw/bolt	XXX (XX.X%)	XXX (XX.X%)		
Rupture of intramedullary nail	XXX (XX.X%)	XXX (XX.X%)		
Displacement of screw/bolt	XXX (XX.X%)	XXX (XX.X%)		
Displacement of intramedullary nail	XXX (XX.X%)	XXX (XX.X%)		
Fracture line				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Clear	XXX (XX.X%)	XXX (XX.X%)	1.111111	1.111111
Vague	XXX (XX.X%)	XXX (XX.X%)		
Disappeared	XXX (XX.X%)	XXX (XX.X%)		
Callus	11111 (111111/0)	(11111/0)		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
NA	XXX (XX.X%)	XXX (XX.X%)		
Intermittent	XXX (XX.X%)	XXX (XX.X%)		
Continuous	XXX (XX.X%)	XXX (XX.X%)		
The frontal/lateral X-ray examination		()	oss the fractur	e line
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Determine the fracture union condition	· · · · ·	```		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
No union	XXX (XX.X%)	XXX (XX.X%)		
Union	XXX (XX.X%)	XXX (XX.X%)		

Table 68Statistical analysis results of subjects' X-ray examination at the
fracture site 12 weeks after surgery

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Table 69Statistical analysis results of subjects' AE evaluation 24 weeks
after surgery

Indicator	Study group	Control group	Statistics	P value	
Whether there are adverse events or complications in the subjects after the last follow-up					
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX	
Yes	XXX (XX.X%)	XXX (XX.X%)			
No	XXX (XX.X%)	XXX (XX.X%)			

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 70 Statistical analysis results of subjects' medication records 24 weeks after surgery

Indicator	Study group	Control group	Statistics	P value
Whether new drugs are added to the comedication is changed	oncomitant medicatio	on or whether the ori	iginal concom	itant
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Indicator	Study group	Control group	Statistics	P value
Whether new types of combination the				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator	Study group	Control group	Statistics	P value
Wound healing - healing grade				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
А	XXX (XX.X%)	XXX (XX.X%)		
В	XXX (XX.X%)	XXX (XX.X%)		
С	XXX (XX.X%)	XXX (XX.X%)		
Wound healing - incision category				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Class I	XXX (XX.X%)	XXX (XX.X%)		
Class II	XXX (XX.X%)	XXX (XX.X%)		
Physical sign - Focal tenderness				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
NA	XXX (XX.X%)	XXX (XX.X%)		
Mild	XXX (XX.X%)	XXX (XX.X%)		
Severe	XXX (XX.X%)	XXX (XX.X%)		
Physical sign - Lengthwise percussio	n pain			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
NA	XXX (XX.X%)	XXX (XX.X%)		
Mild	XXX (XX.X%)	XXX (XX.X%)		
Severe	XXX (XX.X%)	XXX (XX.X%)		
Physical sign - Abnormal activity				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Evaluate postoperative weight-bearing	ıg			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX) XXX	X.XXXX	X.XXXX
No weight-bearing	XXX (XX.X%)	(XX.X%)		
Lower degree of weight-bearing (support with two crutches) Higher degree of weight-	XXX (XX.X%)	XXX (XX.X%)		
bearing (support with one crutch)	XXX (XX.X%)	XXX (XX.X%)		
Fully weight-bearing (support without crutch)	XXX (XX.X%)	XXX (XX.X%)		

Table 72Statistical analysis results of subjects' fractures 24 weeks after
surgery

After the investigational device is implanted, whether external fixation is required to enhance the

Medical Research & Biometrics Center, National	Version No.: V1.0	130/129
Center for Cardiovascular Diseases		

stability of the fracture site				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX		
		(XX.X%)		
No	XXX (XX.X%)	XXX		
		(XX.X%)		

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Indicator	Study group	Control group	Statistics	P value
Reduction				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Stable	XXX (XX.X%)	XXX (XX.X%)		
Loss of reduction	XXX (XX.X%)	XXX (XX.X%)		
Is the re-operation required				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Implant				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Good	XXX (XX.X%)	XXX (XX.X%)		
Rupture of screw/bolt	XXX (XX.X%)	XXX (XX.X%)		
Rupture of intramedullary nail	XXX (XX.X%)	XXX (XX.X%)		
Displacement of screw/bolt	XXX (XX.X%)	XXX (XX.X%)		
Displacement of intramedullary nail	XXX (XX.X%)	XXX (XX.X%)		
Fracture line	VVV (VVV)	VVV (VVV)	V VVVV	v vvvv
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Clear	XXX (XX.X%)	XXX (XX.X%)		
Vague	$\begin{array}{c} XXX (XX.X\%) \\ XXX (XX V\%) \end{array}$	$\begin{array}{c} XXX (XX.X\%) \\ XXX (XX Y\%) \end{array}$		
Disappeared Callus	XXX (XX.X%)	XXX (XX.X%)		
	VVV (VVV)	VVV (VVV)	X.XXXX	X.XXXX
Number of subjects (N miss) NA	XXX (XXX)	XXX (XXX)	Λ.ΛΛΛΛ	Λ.ΛΛΛΛ
Intermittent	XXX (XX.X%)	$\begin{array}{c} XXX (XX.X\%) \\ YYY (YY Y\%) \end{array}$		
Continuous	XXX (XX.X%) XXX (XX.X%)	XXX (XX.X%) XXX (XX.X%)		
The frontal/lateral X-ray examination	· · · · ·	· · · · ·	and the free stur	lina
Number of subjects (N miss)		XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XXX) XXX (XX.X%)	$\begin{array}{c} \text{XXX} (\text{XX.X\%}) \\ \text{XXX} (\text{XX.X\%}) \end{array}$	Λ.ΛΛΛΛ	Λ.ΛΛΛΛ
No		· · · · ·		
	XXX (XX.X%)	XXX (XX.X%)		
Determine the fracture union condition		VVV (VVV)	v vvvv	V VVVV
Number of subjects (N miss)	$\begin{array}{c} XXX (XXX) \\ YYY (YY Y0) \end{array}$	XXX (XXX)	X.XXXX	X.XXXX
No union	XXX (XX.X%)	$\begin{array}{c} XXX (XX.X\%) \\ YYY (YY Y\%) \end{array}$		
Union	XXX (XX.X%)	XXX (XX.X%)		

Table 73Statistical analysis results of subjects' x-ray examination at the
fracture site 24 weeks after surgery

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

T 1' /				
Indicator	Study group	Control group	Statistics	P value
White blood cell (WBC)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
$Normal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)		
NE				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
$Normal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)		
Red blood cell (RBC)				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
$Normal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)		
HGB				
Number of subjects (N miss) Normal \rightarrow Abnormal (with	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
$Normal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)		
Platelet				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
$Normal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)		
$Abnormal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)		

Table 74 Statistical analysis results of outcomes of subjects' complete blood count before and after surgery (before surgery → immediately after surgery)

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

Version No.: V1.0

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 74 Statistical analysis results of outcomes of subjects' complete blood count before and after surgery (before surgery → immediately after surgery) (continued)

Indicator	Study group	Control group	Statistics	P value	
INR					
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX	
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)			
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)			
Normal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)			
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)			
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)			
APTT					
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX	
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)			
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)			
$Normal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)			
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)			
$Abnormal \rightarrow Abnormal$	XXX (XX.X%)	XXX (XX.X%)			

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 75 List of subjects with abnormal complete blood count with clinical significance after surgery changed from normal indicators before surgery (before surgery → immediately after surgery)

Indicator	Site No.	Random No.	Group	Age	Gender	Before surgery	Immediately after surgery
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXXX
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXXX

	after surgery)						
Indicator	Study group	Control group	Statistics	P value			
AST							
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX			
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)					
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)					
Normal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)					
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)					
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)					
ALT	· · · · ·						
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX			
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)					
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)					
Normal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)					
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)					
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)					
ALB	()	()					
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX			
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)					
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)					
$Normal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)					
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)					
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)					
CHOL							
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX			
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)					
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)					
Normal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)					
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)					
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)					
TRIG	· · · · ·						
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX			
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)					
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)					
Normal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)					
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)					
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)					

Table 76 Statistical analysis results of outcomes of subjects' blood biochemical test before and after surgery (before surgery → immediately after surgery)

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

Version No.: V1.0

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

	surgery) (con			
Indicator	Study group	Control group	Statistics	P value
CREA				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)		
$Abnormal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)		
$Abnormal \rightarrow Abnormal$	XXX (XX.X%)	XXX (XX.X%)		
BUN				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)		
UREA	()	()		
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)		
$Abnormal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)		
$Abnormal \rightarrow Abnormal$	XXX (XX.X%)	XXX (XX.X%)		
UA				
Number of subjects (N miss) Normal \rightarrow Abnormal (with clinical	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)		
$Abnormal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)		
$Abnormal \rightarrow Abnormal$	XXX (XX.X%)	XXX (XX.X%)		
LDL-C				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Abnormal (without				
clinical significance)	XXX (XX.X%)	XXX (XX.X%)		
Normal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)		
Abnormal \rightarrow Abnormal	XXX (XX.X%)	XXX (XX.X%)		

Table 76 Statistical analysis results of outcomes of subjects' blood biochemical test before and after surgery (before surgery \rightarrow immediately after surgery) (continued 1)

Medical Research & Biometrics Center, National Center for Cardiovascular Diseases

Version No.: V1.0

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

alter surgery) (continueu 2)									
Indicator	Study group	Control group	Statistics	P value					
HDL-C									
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX					
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)							
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)							
$Normal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)							
Abnormal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)							
$Abnormal \rightarrow Abnormal$	XXX (XX.X%)	XXX (XX.X%)							
GLU									
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX					
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)							
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)							
$Normal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)							
$Abnormal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)							
$Abnormal \rightarrow Abnormal$	XXX (XX.X%)	XXX (XX.X%)							
CRP									
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX					
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)							
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)							
$Normal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)							
$Abnormal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)							
$Abnormal \rightarrow Abnormal$	XXX (XX.X%)	XXX (XX.X%)							
Hypersensitive CRP									
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX					
Normal \rightarrow Abnormal (with clinical significance)	XXX (XX.X%)	XXX (XX.X%)							
Normal \rightarrow Abnormal (without clinical significance)	XXX (XX.X%)	XXX (XX.X%)							
Normal \rightarrow Normal	XXX (XX.X%)	XXX (XX.X%)							
$Abnormal \rightarrow Normal$	XXX (XX.X%)	XXX (XX.X%)							
$Abnormal \rightarrow Abnormal$	XXX (XX.X%)	XXX (XX.X%)							

Table 76 Statistical analysis results of outcomes of subjects' blood biochemical test before and after surgery (before surgery → immediately after surgery) (continued 2)

Notes: 1. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Table 77 List of subjects with abnormal blood biochemical test indicators with clinical significance after surgery changed from normal indicators before surgery (before surgery → immediately after surgery)

Indicator	Site No.	Random No.	Group	Age	Gender	Before surgery	Immediately after surgery
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXXX
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXXX

Site No.	Random No.	Group	Age	Gender	Drug name	Indication or reason for medication	For treating AE	Single dose	Unit	Frequency of administration per day	Route of administration	Start date of administration	End date of administration	Still use after completion of the trial
XXX XXX	XXX XXX	XXX XXX	XXX XXX	XXX XXX	XXX XXX	XXX XXX	XXX XXX	XXXX XXXX	XXX XXX	XXX XXX	XXX XXX	XXX XXX	XXX XXX	XXX XXX
					<u></u>									

Table 78 List of concomitant medication of subjects

Site No.	Random No.	Group	Age	Gender	Name of AE (SOC code)	Name of AE (PT code)	Time of postoperative occurrence (day)	Remission time (day)	Severity	Measures taken	Outcome	Correlation with the surgery	Correlation with the investigational device	Withdrawal from the trial due to AEs	Whether it is UADE	Whether it is device failure	Whether it is SAE
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
<u></u>																	

Table 79Specific description on subjects with AEs

Notes: 1. Time of postoperative occurrence (day) = Date of occurrence of AE - Date of surgery; Remission time (day) = End date of AE - Date of occurrence of AE.

Adverse event	S	tudy group	Contr	rol group
	Number of events	Number of subjects (N=XXX)	Number of events	Number of subjects (N=XXX)
Name of AE (SOC code)	XXX	XXX(XX.XX% [#])	XXX	XXX(XX.XX%)
Name of AE (PT code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)
Name of AE (PT code)				
Name of AE (SOC code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)
Name of AE (PT code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)
Name of AE (PT code)				

Table 80Summary of AEs

Notes: 1. #: Percentage of AEs = Number of subjects suffering from AEs/Total number of subjects in the study group or the control group;

2. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

145/129

Adverse event	Study group	Control group	Statistics	P value
Total number of AEs				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Event rate difference (study grow	up-control group) and	95%CI XX.X [2	XX.X; XX.X]	

Table 80Summary of AEs (continued 1)

Notes: 1. The total number of AEs refers to the number of subjects suffering from AEs, and the AEs occur in the subject at least one time, which is considered as "Yes".

2. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

3. The difference of event rate and 95% confidence interval were analyzed by Wald test with continuous correction;

Table 81	Specific	description or	1 subjects v	with investigational	device-related AEs
		I I I I I I I I I I I I I I I I I I I	J		

Site No.	Random No.	Group	Age	Gender	Name of AE (SOC code)	Name of AE (PT code)	Time of postoperative occurrence (day)	Remission time (day)	Severity	Measures taken	Outcome	Correlation with the surgery	Correlation with the investigational device	Withdrawal from the trial due to AEs	Whether it is UADE	Whether it is device failure	Whether it is SAE
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX

Notes: 1. Time of postoperative occurrence (day) = Date of occurrence of AE - Date of surgery; Remission time (day) = End date of AE - Date of occurrence of AE.

Investigational device- related AE	St	udy group	Control group			
	Number of events	Number of subjects (N=XXX)	Number of events	Number of subjects (N=XXX)		
Name of AE (SOC code)	XXX	XXX(XX.XX% [#])	XXX	XXX(XX.XX%)		
Name of AE (PT code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)		
Name of AE (PT code)						
Name of AE (SOC code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)		
Name of AE (PT code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)		
Name of AE (PT code)						

Table 82	Summary of investigational device-related AEs
----------	---

Notes: 1. #: Percentage of investigational device-related AEs = Number of subjects suffering from investigational device-related AEs/Total number of subjects in the study group or the control group;

2: Investigational device-related AEs refer to those "definitely related", "probably related" and "possibly related" with the investigational device;

Investigational device-related AE	Study group	Control group	Statistics	P value
Total number of investigational device-	related AEs			
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Event rate difference (study group-contro	l group) and 95%CI	XX.X [XX.X;	XX.X]	

Table 82 Summary of investigational device-related AEs (continued)

Notes: 1. The total number of investigational device-related AEs refers to the number of subjects suffering

from investigational device-related AEs and the investigational device-related AEs occur in the subject at least one time, which is considered as "Yes".2: Investigational device-related AEs refer to those "definitely related", "probably related" and

2: Investigational device-related AEs refer to those "definitely related", "probably related" and "possibly related" with the investigational device;

3. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

4. The difference of event rate and 95% confidence interval were analyzed by Wald test with continuous correction;

Indicator			control group	• (N=XXX ^{#1})) P
Total number of adverse even	ents				
	XXX ^{#2} ($XX.X^{3}$)	XXX ^{#2} (X	X.X ^{#3})	X.XXXX
Eve	nt difference (study	group-control g	group) and 95%C	XX.X [2	XX.X; XX.X]
Total number of device rela		XX.X ³)	XXX ^{#2} (X	X.X ^{#3})	X.XXXX
Event ra	te difference (stud	y group-control	group) and 95%C	CI XX.X [2	XX.X; XX.X]
Total number of surgery rela			XXX ^{#2} (X	X.X ^{#3})	X.XXXX
	te difference (study	• •	group) and 95%C	CI XX.X [2	XX.X; XX.X]
Notes: 1. Devices related related" or "defini 2. Surgery related a related" or "defin 3.#1: Total numbe #3: Total numb 4. Group t-test is us 5. Investigational d	adverse events are tely related" to the dverse events are the hitely related" to sur- er of subjects; #2: er of events/total missed to analyze Even	the adverse even study devices; he adverse even rgery; Total number of umber of patien at rate difference Fixation Nail A	ts that are "proba of events; ts: the average nu e (study group-co	bly related" or umber of events ontrol group) an	"possible s per subject; id 95%CI

Table 83 Summary of AEs (Number of events per subject)

Indicator	Study group control g	roup statistic	Р	
Severity				
NO. (Nmiss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
mild	XXX (XX.X%)	XXX (XX.X%	o)	
moderate	XXX (XX.X%)	XXX (XX.X%	%)	
severe	XXX (XX.X%)	XXX (XX.X	(%)	
Device related			,	
NO. (Nmiss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Not related	XXX (XX.X	%) XXX (X	(X.X%)	
Unlikely related		%) XXX (X		
Possible related	XXX (XX.X%	$\dot{\mathbf{x}}$ \mathbf{x} \mathbf{x}	K.X%)	
probably related) XXX (XX		
definitely related	XXX (XX.X		· · ·	
Surgery related	×	, , , , , , , , , , , , , , , , , , , ,	,	
NO. (Nmiss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Not related	XXX (XX.X%			
Unlikely related		%) XXX (X	(X.X%)	
possible related	XXX (XX.X%	$\dot{\mathbf{XXX}}$	X.X%)	
probably related) XXX (XX		
definitely related	XXX (XX.)		XX.X%)	

Table 84Statistical analysis results of the severity and the device related
AEs (According subject)

Notes: 1. If more than one adverse event occurred in a subject, the analysis was performed with the highest severity or correlation;

2. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator (N=XXX#1)	Study group (N=XXX#1)		=XXX#1) total
Severity			
mild	XXX#2 (XX.X%#3)	XXX (XX.X%)	XXX (XX.X%)
moderate	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
severe	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
Device related			
Not related	XXX (XX.X%)) XXX (XX.X%)	XXX (XX.X%)
Unlikely related	XXX (XX.X%)) XXX (XX.X%)	XXX (XX.X%)
Possible related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
probably related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
definitely related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
Surgery related			
Not related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
Unlikely related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
possible related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
probably related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
definitely related	XXX (XX.X%	b) XXX (XX.X%) XXX (XX.X%)

Table 85Statistical analysis results of the severity and the device related
AEs (Number of events per subject)

Notes: 1.#1: Total number of subjects; #2: Total number of events;

2.#3: Total number of events/total number of subjects: the average number of events per subject;
3. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II)

						-	*	U					
Site No.	Random No.	Group	Age	Gender	Name of SAE (SOC code)	Name of SAE (PT code)	Time of postoperative occurrence (day)	Remission time (day)	Severity	Outcome	Correlation with the surgery	Correlation with the investigational device	SAE condition
XXX	XXX	XXX	XXX	vvv	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
ΛΛΛ	ΛΛΛ	ΛΛΛ	ΛΛΛ	XXX	ΛΛΛ	ΛΛΛ	ΛΛΛ	ΛΛΛ	ΛΛΛ	ΛΛΛ	ΛΛΛ	ΛΛΛ	ΛΛΛ
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX

Table 86 Specific description on subjects with SAEs

Notes: 1. Time of postoperative occurrence (day) = Date of occurrence of SAE - Date of surgery; Remission time (day) = End date of SAE - Date of occurrence of SAE.

SAE	Sti	ıdy group	Con	Control group			
	Number of events	Number of subjects (N=XXX)	Number of events	Number of subjects (N=XXX)			
Name of SAE (SOC code)	XXX	XXX(XX.XX% [#])	XXX	XXX(XX.XX%)			
Name of SAE (PT code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)			
Name of SAE (PT code)							
Name of SAE (SOC code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)			
Name of SAE (PT code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)			
Name of SAE (PT code)							

Table 87Summary of SAEs

Notes: 1. #: Percentage of SAEs = Number of subjects suffering from SAEs/Total number of subjects in the study group or the control group;

SAE	Study group	Control group	Statistics	P value
Total number of SAEs				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		
Event rate difference (investigation	group-control group) a	und 95%CI XX.	X [XX.X; XX	.X]

Table 87 Summary of SAEs (continued)

Notes: 1. The total number of SAEs refers to the number of subjects suffering from SAEs and the SAEs occur in the subject at least one time, which is considered as "Yes".

2. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

3. The difference of event rate and 95% confidence interval were analyzed by Wald test with continuous correction;

Site No.	Random No.	Group	Age	Gender	Name of SAE (SOC code)	Name of SAE (PT code)	Time of postoperative occurrence (day)	Remission time (day)	Severity	Outcome	Correlation with the surgery	Correlation with the investigational device	SAE condition
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
···													

 Table 88 Specific description on subjects with investigational device-related SAEs

Notes: 1. Time of postoperative occurrence (day) = Date of occurrence of SAE - Date of surgery; Remission time (day) = End date of SAE - Date of occurrence of SAE.

	St	udy group	Control group			
Investigational device-related SAE	Number of events	Number of subjects (N=XXX)	Number of events	Number of subjects (N=XXX)		
Name of SAE (SOC code)	XXX	XXX(XX.XX% [#])	XXX	XXX(XX.XX%)		
Name of SAE (PT code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)		
Name of SAE (PT code)						
Name of SAE (SOC code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)		
Name of SAE (PT code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)		
Name of SAE (PT code)						

Table 89 Summary of investigational device-related SAI
--

Notes: 1. #: Percentage of investigational device-related SAEs = Number of subjects suffering from investigational device-related SAEs/Total number of subjects in the study group or the control group;

2: Investigational device-related SAEs refer to those "definitely related", "probably related" and "possibly related" with the investigational device;

Investigational related SAE	device-	Study group	Control group	Statistics	P value
Total number of investigational dev related SAEs Number of subjects Yes No		XXX (XXX) XXX (XX.X%) XXX (XX.X%)	XXX (XXX) XXX (XX.X%) XXX (XX.X%)	X.XXXX	X.XXXX
Event rate difference	e (investigat	ion group-control gr	oup) and 95%CI	XX.X [XX.X; X	[X.X]

Table 89 Summary of investigational device-related SAEs (continued)

Notes: 1. The total number of investigational device-related SAEs refers to the number of subjects suffering from investigational device-related SAEs and the investigational device-related SAEs occur in the subject at least one time, which is considered as "Yes".

2: Investigational device-related SAEs refer to those "definitely related", "probably related" and "possibly related" with the investigational device;

3. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

4. The difference of event rate and 95% confidence interval were analyzed by Wald test with continuous correction;

Table 90 Summary of SAEs (Number of events per subject)

Indicator	Study group (N=XXX [#]	(N=XX)	K ^{#1}) P
Total number of advers			
	$XXX ^{\#2}(XX.X^{3})$	$XXX^{\#2} (XX.X^{\#3})$	X.XXXX
	Event difference (study group-con	trol group) and 95%C XX.	X [XX.X; XX.X]
Total number of device	e related adverse events XXX ^{#2} (XX.X ³)	XXX ^{#2} (XX.X ^{#3})	X.XXXX
Ev	ent rate difference (study group-con	ntrol group) and 95%CI XX.	X [XX.X; XX.X]
Total number of surger	ry related adverse events XXX ^{#2} (XX.X ³)	XXX ^{#2} (XX.X ^{#3})	X.XXXX
Ev	ent rate difference (study group-con	ntrol group) and 95%CI XX.	X [XX.X; XX.X]
related" or "o 2. Surgery rela related" or '	lated adverse events are the adverse definitely related" to the study devic ated adverse events are the adverse 'definitely related" to surgery; umber of subjects; #2: Total num	ces; events that are "probably related"	-

#3: Total number of events/total number of patients: the average number of events per subject;

- 4. Group t-test is used to analyze Event rate difference (study group-control group) and 95%CI
- 5. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II);

Indicator	Study group control g	group statistic	Р	
Severity				
NO. (Nmiss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
mild	XXX (XX.X%)	XXX (XX.X%)	
moderate	XXX (XX.X%)	XXX (XX.X%	%)	
severe	XXX (XX.X%)	XXX (XX.X	(%)	
Device related			,	
NO. (Nmiss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Not related	XXX (XX.X	(%) XXX (X	(X.X%)	
Unlikely related	XXX (XX.X	(%) XXX (X	(X.X%)	
Possible related	XXX (XX.X%	۵) XXX (XX	K.X%)	
probably related) XXX (XX		
definitely related	XXX (XX.X	· · · · · · · · · · · · · · · · · · ·	· ·	
Surgery related	`	,	,	
NO. (Nmiss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Not related	XXX (XX.X%			
Unlikely related		(%) XXX (X	(X.X%)	
possible related	XXX (XX.X%) XXX (XX	X.X%)	
probably related) XXX (XX		
definitely related	XXX (XX.)		XX.X%)	

Table 91Statistical analysis results of the severity and the device related
SAEs (According subject)

Notes: 1. If more than one adverse event occurred in a subject, the analysis was performed with the highest severity or correlation;

2. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

Indicator (N=XXX#1)	Study group (N=XXX#1)	control group (N=	=XXX#1) total
Severity			
mild	XXX#2 (XX.X%#3)	XXX (XX.X%)	XXX (XX.X%)
moderate	XXX (XX.X%) X	XXX (XX.X%)	XXX (XX.X%)
severe	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
Device related			
Not related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
Unlikely related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
Possible related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
probably related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
definitely related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
Surgery related			
Not related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
Unlikely related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
possible related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
probably related	XXX (XX.X%)	XXX (XX.X%)	XXX (XX.X%)
definitely related	XXX (XX.X%)) XXX (XX.X%)	XXX (XX.X%)

Table 92Statistical analysis results of the severity and the device related
SAEs (Number of events per subject)

Notes: 1.#1: Total number of subjects; #2: Total number of events;

2.#3: Total number of events/total number of subjects: the average number of events per subject;
3. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II)

Site No.	Random No.	Group	Age	Gender	Name of AE (SOC code)	Name of AE (PT code)	Time of postoperative occurrence (day)	Remission time (day)	Severity	Measures taken	Outcome	Correlation with the surgery	Correlation with the investigational device	Withdrawal from the trial due to AEs	Whether it is device failure	Whether it is SAE
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX

Table 93Specific description on subjects with UADEs

Notes: 1. Time of postoperative occurrence (day) = Date of occurrence of AE - Date of surgery; Remission time (day) = End date of AE - Date of occurrence of AE.

UADE	S	tudy group	Control group			
	Number of events	Number of subjects (N=XXX)	Number of events	Number of subjects (N=XXX)		
Name of adverse reaction (SOC code)	XXX	XXX(XX.XX% [#])	XXX	XXX(XX.XX%)		
Name of adverse reaction (PT code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)		
Name of adverse reaction (PT code)						
Name of adverse reaction (SOC code)	XXX	XXX(XX.XX% [#])	XXX	XXX(XX.XX%)		
Name of adverse reaction (PT code)	XXX	XXX(XX.XX%)	XXX	XXX(XX.XX%)		
Name of adverse reaction (PT code)						

Table 94Summary of UADEs

Notes: 1. #: Percentage of adverse reactions = Number of subjects suffering from adverse reactions/Total number of subjects in the study group or the control group;

	-		· · · · · · · · · · · · · · · · · · ·	
UADE	Study group	Control group	Statistics	P value
Total number of UADEs				
Number of subjects (N miss)	XXX (XXX)	XXX (XXX)	X.XXXX	X.XXXX
Yes	XXX (XX.X%)	XXX (XX.X%)		
No	XXX (XX.X%)	XXX (XX.X%)		

Table 94 Summary of UADEs (continued)

 INO
 AAA (AA.A%)
 AAA (AX.A%)

 Event rate difference (investigation group-control group) and 95%CI
 XX.X [XX.X; XX.X]

Notes: 1. The total number of UADEs refers to the number of subjects suffering from UADE, and the UADE occur in the subject at least one time, which is considered as "Yes".

2. The likelihood ratio Chi-square test or Fisher's exact probability test is used to analyze the intergroup comparison of qualitative indicators;

3. The difference of event rate and 95% confidence interval were analyzed by Wald test with continuous correction;

4. Investigational device: Trochanteric Fixation Nail Advanced (TFNA); control device: Proximal Femoral Nail Antirotation (PFNA-II)

Center for Cardiovascular Diseases